<SEC-DOCUMENT>0001564590-22-005702.txt : 20220218
<SEC-HEADER>0001564590-22-005702.hdr.sgml : 20220218
<ACCEPTANCE-DATETIME>20220218161057
ACCESSION NUMBER:		0001564590-22-005702
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220216
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220218
DATE AS OF CHANGE:		20220218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				364787690
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38445
		FILM NUMBER:		22652831

	BUSINESS ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-944-6104

	MAIL ADDRESS:	
		STREET 1:		642 NEWTOWN YARDLEY ROAD
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC
		DATE OF NAME CHANGE:	20180517

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HELIUS MEDICAL TECHNOLOGIES, INC.
		DATE OF NAME CHANGE:	20140613
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>hsdt-8k_20220216.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-18T19:18:11.5807392+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : cec83a0f4df2417cb0146cca29b59f8d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:hsdt="http://www.heliusmedical.com/20220216" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
hsdt-8k_20220216.htm
</title>
</head>
<!-- NG Converter v5.0.2.70 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001610853_20220216_20220216">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0001610853_20220216_20220216">0001610853</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="hsdt-20220216.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001610853_20220216_20220216">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001610853</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-02-16</xbrli:startDate>
					<xbrli:endDate>2022-02-16</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001610853_20220216_20220216">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001610853_20220216_20220216" format="ixt:datemonthdayyearen">February 16, 2022</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported) </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gruxbwvmsjji000001.jpg" title="" alt="" style="width:149px;height:69px;" /></p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0001610853_20220216_20220216">HELIUS MEDICAL TECHNOLOGIES, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:stateprovnameen">delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0001610853_20220216_20220216">001-38445</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001610853_20220216_20220216">36-4787690</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0001610853_20220216_20220216">642 Newtown Yardley Road</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0001610853_20220216_20220216">Suite 100</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0001610853_20220216_20220216">Newtown</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0001610853_20220216_20220216">PA</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntityAddressPostalZipCode" contextRef="C_0001610853_20220216_20220216">18940</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="line-height:2pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric id="F_000014" name="dei:CityAreaCode" contextRef="C_0001610853_20220216_20220216">(215)</ix:nonNumeric> <ix:nonNumeric id="F_000015" name="dei:LocalPhoneNumber" contextRef="C_0001610853_20220216_20220216">944-6100</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report)</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:WrittenCommunications" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SolicitingMaterial" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementTenderOffer" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:5%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="margin-top:9pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001610853_20220216_20220216">Common Stock</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:TradingSymbol" contextRef="C_0001610853_20220216_20220216">HSDT</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:SecurityExchangeName" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001610853_20220216_20220216" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:8.33%;"></td>
<td style="width:91.67%;"></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><span style="font-weight:bold;color:#000000;">Item 5.02</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Departure of Directors or Certain Officers&#59; Election of Directors&#59; Appointment of Certain Officers&#59; Compensatory Arrangements of Certain Officers.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Helius Medical Technologies, Inc. 2022 Equity Incentive Plan</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 16, 2022, the Board of Directors (the &#8220;Board&#8221;) of Helius Medical Technologies, Inc. (the &#8220;Company&#8221;) adopted the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the &#8220;2022 Plan&#8221;). The effectiveness of the 2022 Plan and the grants made thereunder, as described below, are subject to stockholder approval. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Awards<span style="font-style:normal;">. The 2022 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants, including employees and consultants of the Company&#8217;s affiliates.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Authorized Shares<span style="font-style:normal;">. Initially, the maximum number of shares of the Company&#8217;s Class A Common Stock (the &#8220;Common Stock&#8221;), that may be issued under the 2022 Plan after it becomes effective may not exceed 1,121,272 shares of Common Stock. In addition, the number of shares of Common Stock reserved for issuance under the 2022 Plan would automatically increase on January 1 of each calendar year, starting on January 1, 2023 through January 1, 2027, to an amount equal to (i) 20% of the fully diluted number of shares of Common Stock outstanding on December 31 of the fiscal year before the date of each automatic increase, or (ii) a lesser number of shares determined by the Board prior to the date of the increase. The maximum number of shares of Common Stock that may be issued on the exercise of ISOs under the 2022 Plan is 11,212,720.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to stock awards granted under the 2022 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares do not reduce the number of shares available for issuance under the 2022 Plan. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax withholding obligation do not reduce the number of shares available for issuance under the 2022 Plan. If any shares of Common Stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by the Company (1) because of a failure to meet a contingency or condition required for the vesting of such shares&#59; (2) to satisfy the exercise, strike or purchase price of an award&#59; or (3) to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the 2022 Plan. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Plan Administration<span style="font-style:normal;">. The Board, or a duly authorized committee of the Board, will administer the 2022 Plan and is referred to as the &#8220;plan administrator&#8221;. The Board may also delegate to one or more of the Company&#8217;s officers the authority to: (1) designate employees (other than officers) to receive specified stock awards&#59; and (2) determine the number of shares subject to such stock awards. Under the 2022 Plan, the Board has the authority to determine award recipients, grant dates, the numbers and types of stock awards to be granted, the applicable fair market value, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock award.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2022 Plan, the Board also generally has the authority to effect, with the consent of any materially adversely affected participant, (A) the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right&#59; (B) the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of other awards, cash, or other consideration&#59; or (C) any other action that is treated as a repricing under U.S. generally accepted accounting principles.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options<span style="font-style:normal;">. ISOs and NSOs are granted under stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for stock options, within the terms and conditions of the 2022 Plan&#59; provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of Common Stock on the date of grant. Options granted under the 2022 Plan vest at the rate specified in the stock option agreement as determined by the plan administrator.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The plan administrator determines the term of stock options granted under the 2022 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#8217;s stock option agreement provide otherwise, if an optionholder&#8217;s service relationship with the Company or any of its affiliates ceases for any reason other than disability, death, or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an optionholder&#8217;s service relationship with the Company or any of its affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#8217;s service relationship with the Company or any of its affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include: (1) cash, check, bank draft or money order: (2) a broker-assisted cashless exercise&#59; (3) the tender of shares of Common Stock previously owned by the optionholder&#59; (4) a net exercise of the option if it is an NSO&#59; or (5) other legal consideration approved by the plan administrator. Unless the plan administrator provides otherwise, options or stock appreciation rights generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the plan administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital settlement agreement, or other divorce or separation instrument.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Tax Limitations on ISOs<span style="font-style:normal;">. The aggregate fair market value, determined at the time of grant, of Common Stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of the Company&#8217;s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of the Company total combined voting power or that of any of its parent or subsidiary corporations unless: (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant&#59; and (2) the term of the ISO does not exceed five years from the date of grant.</span></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While grants under the 2022 Plan may be made to our employees prior to such time as the plan is approved by our stockholders, any such grants will not be exercisable until shareholder approval of the 2022 Plan is obtained and any grants made prior to approval will be forfeited and cancelled if the 2022 Plan is not approved by our stockholders.  A copy of the 2022 Plan is included as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Awards to Executive Officers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 16, 2022, the Board approved grants to Dane C. Andreeff, the Company&#8217;s President and Chief Executive Officer, Jeffrey S. Mathiesen, the Company&#8217;s Chief Financial Officer and Treasurer, and Antonella Favit-Van Pelt, the Company&#8217;s Chief Medical Officer, of special stock option awards. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ms. Favit-Van Pelt&#8217;s stock option award was granted pursuant to the Company&#8217;s 2018 Omnibus Incentive Plan, as amended (the &#8220;2018 Plan&#8221;), and Mr. Andreeff&#8217;s and Mr. Mathiesen&#8217;s stock option awards were granted pursuant to the 2022 Plan.&#160;&#160;Each of the option awards was recommended to the Board by the Compensation Committee in recognition of each executive officer&#8217;s continuing service to the Company. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the option awards, Mr. Andreeff will have the right to purchase up to 175,000 shares of the Company&#8217;s Class A Common Stock, Mr. Mathiesen will have the right to purchase up to 37,000 shares of the Company&#8217;s Class A Common Stock, and Ms. Favit-Van Pelt has the right to purchase up to 30,000 shares of the Company&#8217;s Class A Common Stock. The option awards each have an exercise price per share equal to the closing price of the Class A Common Stock of the Company on February 16, 2022, the date of grant, and has a 10 year term. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option award granted to Ms. Favit-Van Pelt vests in 12 equal amounts on the last day of each fiscal quarter, beginning on March 31, 2022.&#160;&#160;1/6<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of each of the option awards granted to Mr. Andreeff and Mr. Mathiesen will vest on June 30, 2022, contingent upon and following stockholder approval of the 2022 Plan, and the remainder of each award will vest in 10 equal amounts on the last day of each fiscal quarter thereafter. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The option awards will be evidenced by stock option grant notices and option agreements substantially in the forms included as Exhibit 10.2 and 10.3 to this Current Report on Form 8-K and incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01 </p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements and Exhibits.</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> (d) Exhibits </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:86.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No. </p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Description </p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1 </p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hsdt-ex101_8.htm"><span style="text-decoration:underline;">Helius Medical Technologies, Inc. 2022 Equity Incentive Plan</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2 </p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1610853/000156459018028537/hsdt-ex103_18.htm"><span style="text-decoration:underline;">Helius Medical Technologies, Inc. 2018 Omnibus Incentive Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.3 to the Form 10-Q filed November 8, 2018)</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3 </p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="hsdt-ex103_9.htm"><span style="text-decoration:underline;">Helius Medical Technologies, Inc. 2022 Equity Incentive Plan Form of Option Grant Agreement</span></a></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;104</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within Inline XBRL document)</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HELIUS MEDICAL TECHNOLOGIES, INC.</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: February 18, 2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jeffrey S. Mathiesen</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jeffrey S. Mathiesen</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Treasurer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>hsdt-ex101_8.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hsdt-ex101_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.70 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.1</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc80716974"></a>HELIUS MEDICAL TECHNOLOGIES, INC. </p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 EQUITY INCENTIVE PLAN<br /><br />ADOPTED BY THE BOARD OF DIRECTORS: February 16, 2022<br />APPROVED BY THE STOCKHOLDERS: May [&#9679;], 2022</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">GENERAL.</font><font style="font-weight:normal;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Successor to and Continuation of Prior Plan.</font><font style="font-weight:normal;color:#000000;"> The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i)&#160;no additional awards may be granted under the Prior Plan; (ii)&#160;any Returning Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii)&#160;all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to the terms of this Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Plan Purpose.</font><font style="font-weight:normal;color:#000000;"> The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Available Awards.</font><font style="font-weight:normal;color:#000000;"> The Plan provides for the grant of the following Awards: (i)&#160;Incentive Stock Options; (ii)&#160;Nonstatutory Stock Options; (iii)&#160;SARs; (iv) Restricted Stock Awards; (v)&#160;RSU Awards; (vi)&#160;Performance Awards; and (vii)&#160;Other Awards. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Adoption Date; Effective Date. </font><font style="font-weight:normal;color:#000000;">The Plan will come into existence on the Adoption Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:uppercase;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716975"></a><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;text-transform:none;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">SHARES SUBJECT TO THE PLAN. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Share Reserve. </font><font style="font-weight:normal;color:#000000;">Subject to adjustment in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(c)</font><font style="font-weight:normal;color:#000000;"> and any adjustments as necessary to implement any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 1,121,272 shares, which is the sum of: (i)&#160;360,000 new shares, plus (ii)&#160;the number of Returning Shares, if any, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1st of each year for a period of five years commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2027, to an amount equal to 20% of the Fully Diluted Shares as of the last day of the preceding calendar year; provided, however that the Board may act prior to the effective date of any such annual increase to provide that the increase for such year will be a lesser number of shares of Common Stock. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Aggregate Incentive Stock Option Limit.</font><font style="font-weight:normal;color:#000000;"> Notwithstanding anything to the contrary in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(a)</font><font style="font-weight:normal;color:#000000;"> and subject to any adjustments as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is 11,212,720 shares. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Share Reserve Operation</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limit Applies to Common Stock Issued Pursuant to Awards. </font><font style="font-weight:normal;color:#000000;">For clarity, the Share Reserve is a limit on the number of shares of Common Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards. Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE Listed Company Manual Section&#160;303A.08, NYSE American Company Guide Section&#160;711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Actions that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve.</font><font style="font-weight:normal;color:#000000;"> The following actions do not result in an issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance under the Plan: (1)&#160;the expiration or termination of any portion of an Award without the shares covered by such portion of the Award having been issued; (2)&#160;the settlement of any portion of an Award in cash (</font><font style="font-style:italic;font-weight:normal;color:#000000;">i.e.</font><font style="font-weight:normal;color:#000000;">, the Participant receives cash rather than Common Stock); (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase price of an Award; or (4)&#160;the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation in connection with an Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Reversion of Previously Issued Shares of Common Stock to Share Reserve.</font><font style="font-weight:normal;color:#000000;"> The following shares of Common Stock previously issued pursuant to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available for issuance under the Plan: (1)&#160;any shares that are forfeited back to or repurchased by the Company because of a failure to meet a contingency or condition required for the vesting of such shares; (2)&#160;any shares that are reacquired by the Company to satisfy the exercise, strike or purchase price of an Award; and (3)&#160;any shares that are reacquired by the Company to satisfy a tax withholding obligation in connection with an Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716976"></a><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ELIGIBILITY AND LIMITATIONS. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Eligible Award Recipients.</font><font style="font-weight:normal;color:#000000;"> Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Specific Award Limitations. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitations on Incentive Stock Option Recipients.</font><font style="font-weight:normal;color:#000000;"> Incentive Stock Options may be granted only to Employees of the Company or a &#8220;parent corporation&#8221; or &#8220;subsidiary corporation&#8221; thereof (as such terms are defined in Sections 424(e) and (f)&#160;of the Code). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Incentive Stock Option $100,000 Limitation.</font><font style="font-weight:normal;color:#000000;"> To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitations on Incentive Stock Options Granted to Ten Percent Stockholders.</font><font style="font-weight:normal;color:#000000;"> A Ten Percent Stockholder may not be granted an Incentive Stock Option unless (i)&#160;the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Option and (ii)&#160;the Option is not exercisable after the expiration of five years from the date of grant of such Option. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Limitations on Nonstatutory Stock Options and SARs.</font><font style="font-weight:normal;color:#000000;"> Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &#8220;parent&#8221; of the Company (as such term is defined in Rule&#160;405) unless the stock underlying such Awards is treated as &#8220;service recipient stock&#8221; under Section&#160;409A because the Awards are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution requirements of Section&#160;409A. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Aggregate Incentive Stock Option Limit.</font><font style="font-weight:normal;color:#000000;"> The aggregate maximum number of shares of the Common Stock that may be issued pursuant to the exercise of Incentive Stock Options is the number of shares specified in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(b)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Employee Director Compensation Limit. </font><font style="font-weight:normal;color:#000000;">The aggregate value of all compensation granted or paid, as applicable, to any individual for service as a Non-Employee Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such Non-Employee Director, will not exceed (i) $750,000 in total value or (ii)&#160;in the event such Non-Employee Director is first appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case calculating the value of any equity awards based on the grant date fair value of such equity awards for financial reporting purposes.&#160;The limitations in this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;3(d)</font><font style="font-weight:normal;color:#000000;"> shall apply beginning with the first calendar year that commences following the Effective Date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716977"></a><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">OPTIONS AND STOCK APPRECIATION RIGHTS. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Option and SAR will have such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such Option will be a Nonstatutory Stock Option. The shares purchased upon exercise of each type of Option will be accounted for separately. Each SAR will be denominated in shares of the Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however, that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Term.</font><font style="font-weight:normal;color:#000000;"> Subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;3(b)</font><font style="font-weight:normal;color:#000000;"> regarding Incentive Stock Options granted to Ten Percent Stockholders, no Option or SAR will be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exercise or Strike Price.</font><font style="font-weight:normal;color:#000000;"> Subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;3(b)</font><font style="font-weight:normal;color:#000000;"> regarding Ten Percent Stockholders, the exercise or strike price of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exercise Procedure and Payment of Exercise Price for Options.</font><font style="font-weight:normal;color:#000000;"> In order to exercise an Option, the Participant must provide notice of exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company. The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability to use certain methods) and to grant Options that require the </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">consent of the Company to utilize a particular method of payment. The exercise price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following methods of payment to the extent set forth in the Option Agreement: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">by cash or check, wire, bank draft or money order (or an electronic equivalent thereof) payable to the Company; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">pursuant to a &#8220;cashless exercise&#8221; program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the exercise price to the Company from the sales proceeds; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">by delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&#160;at the time of exercise the Common Stock is publicly traded, (2)&#160;any remaining balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3)&#160;such delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4)&#160;any certificated shares are endorsed or accompanied by an executed assignment separate from certificate, and (5)&#160;such shares have been held by the Participant for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price, provided that (1)&#160;such shares used to pay the exercise price will not be exercisable thereafter and (2)&#160;any remaining balance of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">in any other form of consideration that may be acceptable to the Board and permissible under Applicable Law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Exercise Procedure and Payment of Appreciation Distribution for SARs.</font><font style="font-weight:normal;color:#000000;"> In order to exercise any SAR, the Participant must provide notice of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon the exercise of a SAR will not be greater than an amount equal to the excess of (i)&#160;the aggregate Fair Market Value on the date of exercise of a number of shares of the Common Stock equal to the number of the Common Stock equivalents that are vested and being exercised under such SAR, over (ii)&#160;the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form of the Common Stock or cash (or any combination of the Common Stock and cash) or in any other form of payment, as determined by the Board and specified in the SAR Agreement. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Transferability.</font><font style="font-weight:normal;color:#000000;"> Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR may be transferred for consideration and </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided, further</font><font style="font-weight:normal;color:#000000;">, that if an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer: </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Restrictions on Transfer.</font><font style="font-weight:normal;color:#000000;"> An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant&#8217;s request, including to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section&#160;671 of the Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into a transfer and other agreements required by the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Domestic Relations Orders.</font><font style="font-weight:normal;color:#000000;"> Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to a domestic relations order. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Vesting.</font><font style="font-weight:normal;color:#000000;"> The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Options and SARs will cease upon termination of the Participant&#8217;s Continuous Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination of Continuous Service for Cause.</font><font style="font-weight:normal;color:#000000;"> Except as explicitly otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service is terminated for Cause, the Participant&#8217;s Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject to the forfeited Award, or any consideration in respect of the forfeited Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Post-Termination Exercise Period Following Termination of Continuous Service for Reasons Other than Cause.</font><font style="font-weight:normal;color:#000000;"> Subject to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(i)</font><font style="font-weight:normal;color:#000000;">, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause, the Participant may exercise their Option or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(a)</font><font style="font-weight:normal;color:#000000;">): </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">three months following the date of such termination if such termination is a termination without Cause (other than any termination due to the Participant&#8217;s Disability or death); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">12 months following the date of such termination if such termination is due to the Participant&#8217;s Disability; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">18 months following the date of such termination if such termination is due to the Participant&#8217;s death; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">18 months following the date of the Participant&#8217;s death if such death occurs following the date of such termination but during the period such Award is otherwise exercisable (as provided in (i)&#160;or (ii) above). </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the date of such termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if earlier, prior to the expiration of the </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or any consideration in respect of the terminated Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Restrictions on Exercise; Extension of Exercisability. </font><font style="font-weight:normal;color:#000000;">A Participant may not exercise an Option or SAR at any time that the issuance of shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i)&#160;the exercise of the Participant&#8217;s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise would violate Applicable Law, or (ii)&#160;the immediate sale of any shares of Common Stock issued upon such exercise would violate the Company&#8217;s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after the expiration of its maximum term (as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(a)</font><font style="font-weight:normal;color:#000000;">). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Exempt Employees.</font><font style="font-weight:normal;color:#000000;"> No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act, any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i)&#160;such Participant&#8217;s death or Disability, (ii)&#160;a Corporate Transaction in which such Award is not assumed, continued or substituted, (iii)&#160;a Change in Control, or (iv)&#160;such Participant&#8217;s retirement (as such term may be defined in the Award Agreement or another applicable agreement or, in the absence of any such definition, in accordance with the Company&#8217;s then current employment policies and guidelines). This </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(j)</font><font style="font-weight:normal;color:#000000;"> is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting of an Option or SAR will be exempt from their regular rate of pay. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Whole Shares.</font><font style="font-weight:normal;color:#000000;"> Options and SARs may be exercised only with respect to whole shares of the Common Stock or their equivalents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716978"></a><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Restricted Stock Awards and RSU Awards.</font><font style="font-weight:normal;color:#000000;"> Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Form of Award</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">RSAs</font><font style="font-weight:normal;color:#000000;">. To the extent consistent with the Company&#8217;s Bylaws, at the Board&#8217;s election, shares of the Common Stock subject to a Restricted Stock Award may be (A)&#160;held in book entry form subject to the Company&#8217;s instructions until such shares become vested or any other restrictions lapse, or (B)&#160;evidenced by a certificate, which certificate will be held in such form and manner as determined by the Board. Unless otherwise determined by the Board, a Participant will have </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">voting and other rights as a stockholder of the Company with respect to any shares subject to a Restricted Stock Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">RSUs</font><font style="font-weight:normal;color:#000000;">. An RSU Award represents a Participant&#8217;s right to be issued on a future date the number of shares of the Common Stock that is equal to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor of the Company with respect to the Company&#8217;s unfunded obligation, if any, to issue shares of the Common Stock in settlement of such Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares are actually issued in settlement of a vested RSU Award). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Consideration</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">RSA</font><font style="font-weight:normal;color:#000000;">. A Restricted Stock Award may be granted in consideration for (A)&#160;cash or check, wire, bank draft or money order payable to the Company, (B)&#160;past services to the Company or an Affiliate, or (C)&#160;any other form of consideration (including future services)as the Board may determine and permissible under Applicable Law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">RSU</font><font style="font-weight:normal;color:#000000;">. Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the Participant&#8217;s services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of the Common Stock pursuant to the RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than the Participant&#8217;s services to the Company or an Affiliate) upon the issuance of any shares of the Common Stock in settlement of the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable Law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Vesting. </font><font style="font-weight:normal;color:#000000;">The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant&#8217;s Continuous Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Termination of Continuous Service.</font><font style="font-weight:normal;color:#000000;"> Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#8217;s Continuous Service terminates for any reason, (1)&#160;the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of the Common Stock held by the Participant under their Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and (2)&#160;any portion of their RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further right, title or interest in the RSU Award, the shares of the Common Stock issuable pursuant to the RSU Award, or any consideration in respect of the RSU Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Dividends and Dividend Equivalents. </font><font style="font-weight:normal;color:#000000;">Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares of the Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement). </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(vi)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Settlement of RSU Awards</font><font style="font-weight:normal;color:#000000;">. An RSU Award may be settled by the issuance of shares of the Common Stock or cash (or any combination thereof) or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Performance Awards</font><font style="font-weight:normal;color:#000000;">. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals have been attained will be determined by the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Other Awards</font><font style="font-weight:normal;color:#000000;">. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the time of grant) may be granted either alone or in addition to Awards provided for under </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4</font><font style="font-weight:normal;color:#000000;"> and the preceding provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;5</font><font style="font-weight:normal;color:#000000;">. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of the Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716979"></a><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Capitalization Adjustments</font><font style="font-weight:normal;color:#000000;">. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of shares of the Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve may annually increase pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(a)</font><font style="font-weight:normal;color:#000000;">; (ii) the class(es) and maximum number of shares that may be issued pursuant to the exercise of Incentive Stock Options pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(b)</font><font style="font-weight:normal;color:#000000;">; and (iii)&#160;the class(es) and number of securities and exercise price, strike price or purchase price of the Common Stock subject to outstanding Awards. The Board shall make such adjustments, and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional shares of the Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred to in the preceding provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 6</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Dissolution or Liquidation</font><font style="font-weight:normal;color:#000000;">. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards consisting of vested and outstanding shares of the Common Stock not subject to a forfeiture condition or the Company&#8217;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of the Common Stock subject to the Company&#8217;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however, that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but contingent on its completion. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Corporate Transaction. </font><font style="font-weight:normal;color:#000000;">The following provisions will apply to Awards in the event of a Corporate Transaction, except as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;11</font><font style="font-weight:normal;color:#000000;">, unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Awards May Be Assumed.</font><font style="font-weight:normal;color:#000000;"> In the event of a Corporate Transaction, any surviving or acquiring corporation (or the surviving or acquiring corporation&#8217;s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards for Awards outstanding under the Plan (including but not limited to awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of the Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor&#8217;s parent company, if any), in connection with such Corporate Transaction. A surviving or acquiring corporation (or its applicable parent) may choose to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Awards Held by Current Participants.</font><font style="font-weight:normal;color:#000000;"> In the event of a Corporate Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Corporate Transaction (referred to as the &#8220;</font><font style="font-style:italic;color:#000000;">Current Participants</font><font style="font-weight:normal;color:#000000;">&#8221;), the vesting of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction) that the Board determines (or, if the Board does not determine such a date, to the date that is five (5)&#160;days prior to the effective time of the Corporate Transaction). Awards so accelerated will terminate if not exercised (if applicable) at or prior to the effective time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse (contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that (a)&#160;will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii)&#160;and (b) have multiple vesting levels depending on the level of performance, unless otherwise provided in the Award Agreement or unless otherwise provided by the Board, the vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of a Corporate Transaction in which the Awards are not assumed, continued or substituted for in accordance with </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;6(c)(i)</font><font style="font-weight:normal;color:#000000;">. With respect to the vesting of cash-settled Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii), such cash payment will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required by Section&#160;409A of the Code. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Awards Held by Persons other than Current Participants.</font><font style="font-weight:normal;color:#000000;"> In the event of a Corporate Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided, however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue to be exercised notwithstanding the Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Payment for Awards in Lieu of Exercise.</font><font style="font-weight:normal;color:#000000;"> Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time, to the excess, if any, of (1)&#160;the value of the property the Participant would have received upon the exercise of the Award (including, at the discretion of the Board, any unvested portion of such Award), over (2)&#160;any exercise price payable by such holder in connection with such exercise. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Appointment of Stockholder Representative.</font><font style="font-weight:normal;color:#000000;"> As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant&#8217;s behalf with respect to any escrow, indemnities and any contingent consideration. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Restriction on Right to Undertake Transactions</font><font style="font-weight:normal;color:#000000;">. The grant of any Award under the Plan and the issuance of shares pursuant to any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize any adjustment, recapitalization, reorganization or other change in the Company&#8217;s capital structure or its business, any merger or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into or exchangeable for the Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716980"></a><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ADMINISTRATION. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Administration by Board.</font><font style="font-weight:normal;color:#000000;"> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in subsection (c)&#160;below. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Powers of Board.</font><font style="font-weight:normal;color:#000000;"> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To determine from time to time (1)&#160;which of the persons eligible under the Plan will be granted Awards; (2)&#160;when and how each Award will be granted; (3)&#160;what type or combination of types of Award will be granted; (4)&#160;the provisions of each Award granted (which need not be identical), including the time or times when a person will be permitted to receive an issuance of the Common Stock or other payment pursuant to an Award; (5)&#160;the number of shares of the Common Stock or cash equivalent with respect to which an Award will be granted to each such person; (6)&#160;the Fair Market Value applicable to an Award; and (7)&#160;the terms of any Performance Award that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To settle all controversies regarding the Plan and Awards granted under it. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Common </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Stock or the share price of the Common Stock including any Corporate Transaction, for reasons of administrative convenience. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To amend the Plan in any respect the Board deems necessary or advisable; provided, however</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;"> that stockholder approval will be required for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment of the Plan will not be Materially Impaired by any amendment of the Plan unless (1)&#160;the Company requests the consent of the affected Participant, and (2)&#160;such Participant consents in writing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(viii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To submit any amendment to the Plan for stockholder approval. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ix)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided however</font><font style="font-weight:normal;color:#000000;">, that, a Participant&#8217;s rights under any Award will not be Materially Impaired by any such amendment unless (1)&#160;the Company requests the consent of the affected Participant, and (2)&#160;such Participant consents in writing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Generally, to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(xi)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure or facilitate compliance with the laws of the relevant foreign jurisdiction). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(xii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action, (1)&#160;the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2)&#160;the cancellation of any outstanding Option or SAR and the grant in substitution therefor of (A)&#160;a new Option, SAR, Restricted Stock Award, RSU Award or Other Award, under the Plan or another equity plan of the Company, covering the same or a different number of shares of the Common Stock, (B)&#160;cash and/or (C)&#160;other valuable consideration (as determined by the Board); or (3)&#160;any other action that is treated as a repricing under generally accepted accounting principles. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Delegation to Committee</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">General.</font><font style="font-weight:normal;color:#000000;"> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. Each Committee may retain the authority to concurrently </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">administer the Plan with Committee or subcommittee to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Rule 16b-3 Compliance.</font><font style="font-weight:normal;color:#000000;"> To the extent an Award is intended to qualify for the exemption from Section&#160;16(b) of the Exchange Act that is available under Rule 16b-3 under the Exchange Act, the Award will be granted by the Board or a Committee that consists solely of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) under the Exchange Act and thereafter any action establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent necessary for such exemption to remain available. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Effect of Board&#8217;s Decision.</font><font style="font-weight:normal;color:#000000;"> All determinations, interpretations and constructions made by the Board or any Committee in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Delegation to an Officer.</font><font style="font-weight:normal;color:#000000;"> The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following (i)&#160;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law, other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii)&#160;determine the number of shares of the Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted by the Board or any Committee evidencing such delegation will specify the total number of shares of the Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the Fair Market Value. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716981"></a><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">TAX WITHHOLDING.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Withholding Authorization.</font><font style="font-weight:normal;color:#000000;"> As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares of the Common Stock subject to an Award, unless and until such obligations are satisfied. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Satisfaction of Withholding Obligation.</font><font style="font-weight:normal;color:#000000;"> To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&#160;causing the Participant to tender a cash payment; (ii)&#160;withholding shares of the Common Stock from the shares of the Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&#160;withholding cash from an Award settled in cash; (iv)&#160;withholding payment from any amounts otherwise payable to the Participant; (v)&#160;by allowing a Participant to effectuate a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board; or (vi)&#160;by such other method as may be set forth in the Award Agreement. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Obligation to Notify or Minimize Taxes; No Liability to Claims. </font><font style="font-weight:normal;color:#000000;">Except as required by Applicable Law the Company has no duty or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award. As a condition to accepting an Award under the Plan, each Participant (i)&#160;agrees to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and (ii)&#160;acknowledges that such Participant was advised to consult with their own personal tax, financial and other legal advisors regarding the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant acknowledges any Option or SAR granted under the Plan is exempt from Section&#160;409A only if the exercise or strike price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Withholding Indemnification. </font><font style="font-weight:normal;color:#000000;">As a condition to accepting an Award under the Plan, in the event that the amount of the Company&#8217;s and/or its Affiliate&#8217;s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the Company and/or its Affiliates to withhold the proper amount. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716982"></a><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">MISCELLANEOUS. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Source of Shares.</font><font style="font-weight:normal;color:#000000;"> The stock issuable under the Plan will be shares of authorized but unissued or reacquired shares of the Common Stock, including shares repurchased by the Company on the open market or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Use of Proceeds from Sales of the Common Stock. </font><font style="font-weight:normal;color:#000000;">Proceeds from the sale of shares of the Common Stock pursuant to Awards will constitute general funds of the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Corporate Action Constituting Grant of Awards.</font><font style="font-weight:normal;color:#000000;"> Corporate action constituting a grant by the Company of an Award to any Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Stockholder Rights.</font><font style="font-weight:normal;color:#000000;"> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of the Common Stock subject to such Award unless and until (i)&#160;such Participant has satisfied all requirements for exercise of the Award pursuant to its </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">terms, if applicable, and (ii)&#160;the issuance of the Common Stock subject to such Award is reflected in the records of the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No Employment or Other Service Rights.</font><font style="font-weight:normal;color:#000000;"> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i)&#160;the employment of an Employee with or without notice and with or without cause, (ii)&#160;the service of a Consultant pursuant to the terms of such Consultant&#8217;s agreement with the Company or an Affiliate, or (iii)&#160;the service of a Director pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated, as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Change in Time Commitment.</font><font style="font-weight:normal;color:#000000;"> In the event a Participant&#8217;s regular level of time commitment in the performance of their services for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i)&#160;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&#160;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Execution of Additional Documents.</font><font style="font-weight:normal;color:#000000;"> As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional documents or instruments necessary or desirable, as determined in the Plan Administrator&#8217;s sole discretion, to carry out the purposes or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator&#8217;s request. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Electronic Delivery and Participation.</font><font style="font-weight:normal;color:#000000;"> Any reference herein or in an Award Agreement to a &#8220;written&#8221; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#8217;s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The form of delivery of any the Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Clawback/Recovery.</font><font style="font-weight:normal;color:#000000;"> All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback policy that the Company otherwise adopts, to the extent </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">applicable and permissible under Applicable Law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of the Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant&#8217;s right to voluntarily terminate employment upon a &#8220;resignation for good reason,&#8221; or for a &#8220;constructive termination&#8221; or any similar term under any plan of or agreement with the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Securities Law Compliance. </font><font style="font-weight:normal;color:#000000;">A Participant will not be issued any shares in respect of an Award unless either (i)&#160;the shares are registered under the Securities Act; or (ii)&#160;the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such shares if the Company determines that such receipt would not be in material compliance with Applicable Law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Transfer or Assignment of Awards; Issued Shares.</font><font style="font-weight:normal;color:#000000;"> Except as expressly provided in the Plan or the form of Award Agreement, Awards granted under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of the Trading Policy and Applicable Law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Effect on Other Employee Benefit Plans. </font><font style="font-weight:normal;color:#000000;">The value of any Award granted under the Plan, as determined upon grant, vesting or settlement, shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant&#8217;s benefits under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any Affiliate&#8217;s employee benefit plans. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Deferrals.</font><font style="font-weight:normal;color:#000000;"> To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of the Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section&#160;409A. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Section 409A. </font><font style="font-weight:normal;color:#000000;">Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&#160;409A, and, to the extent not so exempt, in compliance with the requirements of Section&#160;409A. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&#160;409A, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section&#160;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of the Common Stock are publicly traded, and if a Participant holding an Award that constitutes &#8220;deferred compensation&#8221; under Section&#160;409A is a &#8220;specified employee&#8221; for purposes of Section&#160;409A, no distribution or payment of any amount that is due because of a &#8220;separation from service&#8221; (as defined in Section&#160;409A without regard to alternative definitions thereunder) will be issued or paid before the date that is six months and one day following the date of such Participant&#8217;s &#8220;separation from service&#8221; or, if earlier, the date of the Participant&#8217;s death, unless such distribution or payment can be </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">made in a manner that complies with Section&#160;409A, and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Choice of Law. </font><font style="font-weight:normal;color:#000000;">This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of any law other than the law of the State of Delaware. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716983"></a><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">COVENANTS OF THE COMPANY. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will seek to obtain from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be required to grant Awards and to issue and sell shares of the Common Stock upon exercise or vesting of the Awards; provided, however, that this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of the Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell the Common Stock upon exercise or vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent issuance of the Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716984"></a><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ADDITIONAL RULES FOR AWARDS SUBJECT TO SECTION&#160;409A. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Application. </font><font style="font-weight:normal;color:#000000;">Unless the provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;"> of the Plan are expressly superseded by the provisions in the form of Award Agreement, the provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11</font><font style="font-weight:normal;color:#000000;"> shall apply and shall supersede anything to the contrary set forth in the Award Agreement for a Non-Exempt Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Non-Exempt Awards Subject to Non-Exempt Severance Arrangements.</font><font style="font-weight:normal;color:#000000;"> To the extent a Non-Exempt Award is subject to Section&#160;409A due to application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b)&#160;apply. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Non-Exempt Award vests in the ordinary course during the Participant&#8217;s Continuous Service in accordance with the vesting schedule set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will the shares be issued in respect of such Non-Exempt Award any later than the later of: (i)&#160;December 31</font><font style="font-size:8.5pt;font-weight:normal;color:#000000;">st</font><font style="font-weight:normal;color:#000000;"> of the calendar year that includes the applicable vesting date, or (ii)&#160;the 60</font><font style="font-size:8.5pt;font-weight:normal;color:#000000;">th</font><font style="font-weight:normal;color:#000000;"> day that follows the applicable vesting date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant&#8217;s Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and, therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement of such Non-Exempt Award upon the Participant&#8217;s Separation from Service in accordance with the terms of the Non-Exempt Severance Arrangement, but in no event later than the 60</font><font style="font-size:8.5pt;font-weight:normal;color:#000000;">th</font><font style="font-weight:normal;color:#000000;"> day that follows the date of the Participant&#8217;s Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations contained in Section&#160;409A applicable to &#8220;specified employees,&#8221; as defined in Section&#160;409A(a)(2)(B)(i) of the Code, </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">such shares shall not be issued before the date that is six months following the date of such Participant&#8217;s Separation from Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant&#8217;s Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and, therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in the Grant Notice as if they had vested in the ordinary course during the Participant&#8217;s Continuous Service, notwithstanding the vesting acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided under Treasury Regulations Section&#160;1.409A-3(a)(4).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Treatment of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants.</font><font style="font-weight:normal;color:#000000;"> The provisions of this subsection (c)&#160;shall apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of the Non-Exempt Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Vested Non-Exempt Awards</font><font style="font-weight:normal;color:#000000;">. The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Corporate Transaction is also a Section&#160;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Vested Non-Exempt Award. Upon the Section&#160;409A Change in Control the settlement of the Vested Non-Exempt Award will automatically be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&#160;409A Change in Control. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Corporate Transaction is not also a Section&#160;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Unvested Non-Exempt Awards.</font><font style="font-weight:normal;color:#000000;"> The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the Board pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 11(e)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date of the Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction, then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with the requirements of Section&#160;409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(3)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether or not such Corporate Transaction is also a Section&#160;409A Change in Control. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Treatment of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors.</font><font style="font-weight:normal;color:#000000;"> The following provisions of this subsection (d)&#160;shall apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt Director Award in connection with a Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Corporate Transaction is also a Section&#160;409A Change in Control then the Acquiring Entity may not assume, continue or substitute the Non-Exempt Director Award. Upon the Section&#160;409A Change in Control the vesting and settlement of any Non-Exempt Director Award will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award. Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued to the Participant upon the Section&#160;409A Change in Control pursuant to the preceding provision. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Corporate Transaction is not also a Section&#160;409A Change in Control, then the Acquiring Entity must either assume, continue or substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity&#8217;s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value made on the date of the Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the RSU Award is a Non-Exempt Award, then the provisions in this Section&#160;11(e) shall apply and supersede anything to the contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award: </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Any exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates would be in compliance with the requirements of Section&#160;409A. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements of Section&#160;409A, including pursuant to any of the exemptions available in Treasury Regulations Section&#160;1.409A-3(j)(4)(ix).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the extent it is required for compliance with the requirements of Section&#160;409A, the Change in Control or Corporate Transaction event triggering settlement must also constitute a Section&#160;409A Change in Control. To the extent the terms of a Non-Exempt Award provides that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance with the requirements of Section&#160;409A, the termination event triggering settlement must also constitute a Separation From Service. However, if at the time the shares would otherwise be issued to a Participant in connection with a &#8220;separation from service&#8221; such Participant is subject to the distribution limitations contained in Section&#160;409A applicable to &#8220;specified employees,&#8221; as defined in Section&#160;409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following the date of the Participant&#8217;s Separation From Service, or, if earlier, the date of the Participant&#8217;s death that occurs within such six month period. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The provisions in this subsection (e)&#160;for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award are intended to comply with the requirements of Section&#160;409A so that the delivery of the shares to the Participant in respect of such Non-Exempt Award will not trigger the additional tax imposed under Section&#160;409A, and any ambiguities herein will be so interpreted. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716985"></a><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">SEVERABILITY. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If all or any part of the Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716986"></a><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">TERMINATION OF THE PLAN. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board may suspend or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i)&#160;the Adoption Date, or (ii)&#160;the date the Plan is approved by the Company&#8217;s stockholders. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Toc80716987"></a><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">DEFINITIONS. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in the Plan, the following definitions apply to the capitalized terms indicated below: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Acquiring Entity&#8221;</font><font style="font-weight:normal;color:#000000;"> means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Adoption Date</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means the date the Plan is first approved by the Board or Compensation Committee. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Affiliate&#8221;</font><font style="font-weight:normal;color:#000000;"> means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Applicable Law&#8221;</font><font style="font-weight:normal;color:#000000;"> means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution, principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial Industry Regulatory Authority). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means any right to receive the Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Award Agreement&#8221;</font><font style="font-weight:normal;color:#000000;"> means a written agreement between the Company and a Participant evidencing the terms and conditions of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general terms and conditions applicable to the Award and which is provided to a Participant along with the Grant Notice. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Board&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Board of Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and binding on all Participants. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Capitalization Adjustment&#8221;</font><font style="font-weight:normal;color:#000000;"> means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Cause&#8221;</font><font style="font-weight:normal;color:#000000;"> has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i)&#160;the Participant&#8217;s dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers, vendors or other third parties with which such entity does business; (ii)&#160;the Participant&#8217;s commission of (A)&#160;a felony or (B)&#160;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&#160;the Participant&#8217;s failure to perform the Participant&#8217;s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv)&#160;the Participant&#8217;s gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v)&#160;the Participant&#8217;s material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition, nonsolicitation, </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">nondisclosure and/or assignment of inventions. The determination that a termination of the Participant&#8217;s Continuous Service is either for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the Company&#8217;s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for any other purpose. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Change in Control&#8221;</font><font style="font-weight:normal;color:#000000;"> or </font><font style="font-style:italic;color:#000000;">&#8220;Change of Control&#8221;</font><font style="font-weight:normal;color:#000000;"> means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal income tax consequences to the Participant in connection with an Award, also constitutes a Section&#160;409A Change in Control: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">any Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A)&#160;on account of the acquisition of securities of the Company directly from the Company, (B)&#160;on account of the acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#8217;s securities in a transaction or series of related transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C)&#160;solely because the level of Ownership held by any Exchange Act Person (the &#8220;</font><font style="font-style:italic;color:#000000;">Subject Person</font><font style="font-weight:normal;color:#000000;">&#8221;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be deemed to occur; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">there is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&#160;outstanding voting securities representing more than 50% of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&#160;more than 50% of the combined outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other disposition; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">individuals who, on the date the Plan is adopted by the Board, are members of the Board (the </font><font style="font-style:italic;color:#000000;">&#8220;Incumbent Board&#8221;</font><font style="font-weight:normal;color:#000000;">) cease for any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination for </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing or any other provision of this Plan, (A)&#160;the term Change in Control shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&#160;the definition of Change in Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Code&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Committee&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or Compensation Committee in accordance with the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Common Stock&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Class A Common Stock of the Company. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Company&#8221;</font><font style="font-weight:normal;color:#000000;"> means Helius Medical Technologies, Inc., a Delaware corporation. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Compensation Committee&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Compensation Committee of the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Consultant&#8221;</font><font style="font-weight:normal;color:#000000;"> means any person, including an advisor, who is (i)&#160;engaged by the Company or an Affiliate to render consulting or advisory services and is compensated for such services, or (ii)&#160;serving as a member of the board of directors of an Affiliate and is compensated for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered a &#8220;Consultant&#8221; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company&#8217;s securities to such person. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Continuous Service&#8221;</font><font style="font-weight:normal;color:#000000;"> means that the Participant&#8217;s service with the Company or an Affiliate, whether as an Employee, Director or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is no interruption or termination of the Participant&#8217;s service with the Company or an Affiliate, will not terminate a Participant&#8217;s Continuous Service; provided, however</font><font style="font-style:italic;font-weight:normal;color:#000000;">,</font><font style="font-weight:normal;color:#000000;"> that if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, such Participant&#8217;s Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the Chief Executive Officer of the Company, in that party&#8217;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&#160;any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or any other personal leave, or (ii)&#160;transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in the Company&#8217;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law. In addition, to the extent required for exemption from or compliance with </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">Section&#160;409A, the determination of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent with the definition of &#8220;separation from service&#8221; as defined under Treasury Regulation Section&#160;1.409A-1(h) (without regard to any alternative definition thereunder). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Corporate Transaction&#8221;</font><font style="font-weight:normal;color:#000000;"> means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a sale or other disposition of at least 50% of the outstanding securities of the Company; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">a merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of the Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing or any other provision of this Plan, (A)&#160;the term Corporate Transaction shall not include a sale of assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, (B)&#160;the definition of Corporate Transaction (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C)&#160;with respect to any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described in clause (i), (ii), (iii), or (iv)&#160;also constitutes a Section&#160;409A Change in Control if required in order for the payment not to violate Section&#160;409A of the Code. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Director&#8221;</font><font style="font-weight:normal;color:#000000;"> means a member of the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;determine&#8221; </font><font style="font-weight:normal;color:#000000;">or </font><font style="font-style:italic;color:#000000;">&#8220;determined&#8221; </font><font style="font-weight:normal;color:#000000;">means as determined by the Board or the Committee (or its designee) in its sole discretion. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(u)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Disability&#8221;</font><font style="font-weight:normal;color:#000000;"> means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months, as provided in Section&#160;22(e)(3) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Effective Date&#8221;</font><font style="font-weight:normal;color:#000000;"> means the effective date of this Plan, which is the date this Plan (as amended from time to time) is approved by the Company&#8217;s stockholders. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(w)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Employee</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#8220;Employee&#8221; for purposes of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Employer&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Company or the Affiliate of the Company that employs the Participant. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(y)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Entity&#8221; </font><font style="font-weight:normal;color:#000000;">means a corporation, partnership, limited liability company or other entity. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(z)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Exchange Act&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(aa)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Exchange Act Person&#8221;</font><font style="font-weight:normal;color:#000000;"> means any natural person, Entity or &#8220;group&#8221; (within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act), except that &#8220;Exchange Act Person&#8221; will not include (i)&#160;the Company or any Subsidiary of the Company, (ii)&#160;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary of the Company, (iii)&#160;an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&#160;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v)&#160;any natural person, Entity or &#8220;group&#8221; (within the meaning of Section&#160;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&#8217;s then outstanding securities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(bb)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Fair Market Value&#8221;</font><font style="font-weight:normal;color:#000000;"> means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined on a per share or aggregate basis, as applicable) determined as follows: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems reliable. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">In the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(cc)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Fully Diluted Shares&#8221;</font><font style="color:#000000;"> </font><font style="font-weight:normal;color:#000000;">as of a date means an amount equal to the number of shares of Common Stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding Awards under the Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of Common Stock, in each case as of the close of business of the Company on such date and without regard to any vesting conditions or other limitations on the immediate ability to convert, exchange or exercise such rights. For purposes of calculating the number of Fully Diluted Shares, if the number of shares subject to an outstanding right to acquire shares is variable, then the number of shares of Common Stock </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">issuable upon exercise</font><font style="font-weight:normal;color:#000000;">, conversion, exchange</font><font style="font-weight:normal;color:#000000;"> or settlement of the </font><font style="font-weight:normal;color:#000000;">right</font><font style="font-weight:normal;color:#000000;"> shall be the maximum number of shares that could be received under such </font><font style="font-weight:normal;color:#000000;">right</font><font style="font-weight:normal;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(dd)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Governmental Body&#8221; </font><font style="font-weight:normal;color:#000000;">means any: (i)&#160;nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&#160;federal, state, local, municipal, foreign or other government; (iii)&#160;governmental or regulatory body, or quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or&#160;(iv)&#160;self-regulatory organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ee)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Grant Notice&#8221;</font><font style="font-weight:normal;color:#000000;"> means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes the name of the Participant, the type of Award, the date of grant of the Award, number of shares of the Common Stock subject to the Award or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ff)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Incentive Stock Option&#8221;</font><font style="font-weight:normal;color:#000000;"> means an option granted pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4</font><font style="font-weight:normal;color:#000000;"> of the Plan that is intended to be, and qualifies as, an &#8220;incentive stock option&#8221; within the meaning of Section&#160;422 of the Code. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(gg)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Materially Impair&#8221;</font><font style="font-weight:normal;color:#000000;"> means any amendment to the terms of the Award that materially adversely affects the Participant&#8217;s rights under the Award. A Participant&#8217;s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole, does not Materially Impair the Participant&#8217;s rights. For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant&#8217;s rights under the Award: (i)&#160;imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised; (ii)&#160;to maintain the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (iii)&#160;to change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the Award as an Incentive Stock Option under Section&#160;422 of the Code; (iv)&#160;to clarify the manner of exemption from, or to bring the Award into compliance with or qualify it for an exemption from, Section&#160;409A; or (v)&#160;to comply with other Applicable Laws. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(hh)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Non-Employee Director&#8221;</font><font style="font-weight:normal;color:#000000;"> means a Director who either (i)&#160;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation S-K promulgated pursuant to the Securities Act (</font><font style="font-style:italic;color:#000000;">&#8220;Regulation S-K&#8221;</font><font style="font-weight:normal;color:#000000;">)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship for which disclosure would be required pursuant to Item&#160;404(b) of Regulation S-K; or (ii)&#160;is otherwise considered a &#8220;non-employee director&#8221; for purposes of Rule 16b-3.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Non-Exempt Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means any Award that is subject to, and not exempt from, Section&#160;409A, including as the result of (i)&#160;a deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii)&#160;the terms of any Non-Exempt Severance Agreement. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(jj)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Non-Exempt Director Award</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable grant date. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(kk)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Non-Exempt Severance Arrangement&#8221; </font><font style="font-weight:normal;color:#000000;">means a severance arrangement or other agreement between the Participant and the Company that provides for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant&#8217;s termination of employment or separation from service (as such term is defined in Section&#160;409A(a)(2)(A)(i) of the Code (and without regard to any alternative definition thereunder) (</font><font style="font-style:italic;color:#000000;">&#8220;Separation from Service&#8221;</font><font style="font-weight:normal;color:#000000;">) and such severance benefit does not satisfy the requirements for an exemption from application of Section&#160;409A provided under Treasury Regulations Section&#160;1.409A-1(b)(4), 1.409A-1(b)(9) or otherwise. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ll)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Nonstatutory Stock Option&#8221; </font><font style="font-weight:normal;color:#000000;">means any option granted pursuant to </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4</font><font style="font-weight:normal;color:#000000;"> of the Plan that does not qualify as an Incentive Stock Option. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(mm)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Officer&#8221;</font><font style="font-weight:normal;color:#000000;"> means a person who is an officer of the Company within the meaning of Section&#160;16 of the Exchange Act. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(nn)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Option&#8221;</font><font style="font-weight:normal;color:#000000;"> means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of the Common Stock granted pursuant to the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(oo)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Option Agreement&#8221;</font><font style="font-weight:normal;color:#000000;"> means a written agreement between the Company and the Optionholder evidencing the terms and conditions of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of the general terms and conditions applicable to the Option and which is provided to a Participant along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(pp)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Optionholder&#8221;</font><font style="font-weight:normal;color:#000000;"> means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(qq)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Other Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means an award based in whole or in part by reference to the Common Stock which is granted pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;5(c)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(rr)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Other Award Agreement&#8221;</font><font style="font-weight:normal;color:#000000;"> means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ss)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Own&#8221;</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-style:italic;color:#000000;"> &#8220;Owned&#8221;</font><font style="font-weight:normal;color:#000000;">,</font><font style="font-style:italic;color:#000000;"> &#8220;Owner&#8221; </font><font style="font-weight:normal;color:#000000;">or </font><font style="font-style:italic;color:#000000;">&#8220;Ownership&#8221;</font><font style="font-weight:normal;color:#000000;"> means that a person or Entity will be deemed to &#8220;Own,&#8221; to have &#8220;Owned,&#8221; to be the &#8220;Owner&#8221; of, or to have acquired &#8220;Ownership&#8221; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(tt)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Participant&#8221;</font><font style="font-weight:normal;color:#000000;"> means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(uu)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Performance Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;5(b)</font><font style="font-weight:normal;color:#000000;"> pursuant to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are settled in </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common Stock. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Performance Criteria&#8221;</font><font style="font-weight:normal;color:#000000;"> means one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average stockholder&#8217;s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction; stockholders&#8217; equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of net income or operating income; billings; product development goals; financing; regulatory milestones, including approval of a product; stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress of internal research;&nbsp;&nbsp;progress of partnered programs; partner satisfaction; budget management; data from clinical studies, partner or collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives relates to process development activities);  employee retention; strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); establishing relationships with commercial entities with respect to the marketing, distribution and sale of the Company&#8217;s products; supply chain achievements; co-development, co-marketing, profit sharing, joint venture or other similar arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the Board or Committee whether or not listed herein. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ww)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Performance Goals&#8221;</font><font style="font-weight:normal;color:#000000;"> means, for a Performance Period, one or more goals established by the Board for the Performance Period based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i)&#160;in the Award Agreement at the time the Award is granted or (ii)&#160;in such other document setting forth the Performance Goals at the time the Performance Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (1)&#160;to exclude restructuring and/or other nonrecurring charges; (2)&#160;to exclude exchange rate effects; (3)&#160;to exclude the effects of changes to generally accepted accounting principles; (4)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (6)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (7)&#160;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a Performance Period following such divestiture; (8)&#160;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&#160;to exclude the effects of stock based compensation and the award of bonuses under the Company&#8217;s bonus plans; (10)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (11)&#160;to exclude the goodwill and intangible asset impairment charges that are required to </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">be recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in the Award Agreement at the time the Award is granted or in such other document setting for the Performance Goals at the time the Performance Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance Period. Partial achievement of the specified criteria may result in the </font><font style="font-weight:normal;color:#000000;">payment or vesting corresponding to the degree of achievement as specified in the Award Agreement or the written terms of a Performance Cash Award. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(xx)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Performance Period&#8221; </font><font style="font-weight:normal;color:#000000;">means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#8217;s right to vesting or exercise of an Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(yy)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Plan&#8221;</font><font style="font-weight:normal;color:#000000;"> means this Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended from time to time. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(zz)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Plan Administrator&#8221; </font><font style="font-weight:normal;color:#000000;">means the person, persons, and/or third-party administrator designated by the Company to administer the day to day operations of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(aaa)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Post-Termination Exercise Period&#8221; </font><font style="font-weight:normal;color:#000000;">means the period following termination of a Participant&#8217;s Continuous Service within which an Option or SAR is exercisable, as specified in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(h)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(bbb)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Prior Plan&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Helius Medical Technologies, Inc. 2018 Omnibus Incentive Plan, as amended.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ccc)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Prospectus&#8221;</font><font style="font-weight:normal;color:#000000;"> means the document containing the Plan information specified in Section&#160;10(a) of the Securities Act. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ddd)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;"> &#8220;Restricted Stock Award&#8221;</font><font style="font-weight:normal;color:#000000;"> or </font><font style="font-style:italic;color:#000000;">&#8220;RSA&#8221;</font><font style="font-weight:normal;color:#000000;"> means an Award of shares of the Common Stock which is granted pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;5(a)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(eee)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Restricted Stock Award Agreement&#8221; </font><font style="font-weight:normal;color:#000000;">means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the Restricted Stock Award and which is provided to a Participant along with the Grant Notice. Each Restricted Stock Award Agreement will be subject to the terms and conditions of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(fff)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Returning Shares&#8221;</font><font style="font-weight:normal;color:#000000;"> means shares subject to outstanding stock awards granted under the Prior Plan and that following the Effective Date:&#160;(A)&#160;are not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued;&#160;(B)&#160;are not issued because such stock award or any portion thereof is settled in cash;&#160;(C)&#160;are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares;&#160;(D)&#160;are withheld or reacquired to satisfy the exercise, strike or purchase price; or&#160;(E)&#160;are withheld or reacquired to satisfy a tax withholding obligation. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(ggg)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">RSU Award</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> or </font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">RSU</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means an Award of restricted stock units representing the right to receive an issuance of shares of the Common Stock which is granted pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;5(a)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(hhh)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;RSU Award Agreement&#8221;</font><font style="font-weight:normal;color:#000000;"> means a written agreement between the Company and a holder of an RSU Award evidencing the terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing the written summary of the general terms and conditions applicable to the RSU Award and which is provided to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Rule 16b-3&#8221;</font><font style="font-weight:normal;color:#000000;"> means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(jjj)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Rule 405&#8221;</font><font style="font-weight:normal;color:#000000;"> means Rule 405 promulgated under the Securities Act. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(kkk)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Section&#160;409A&#8221;</font><font style="font-weight:normal;color:#000000;"> means Section&#160;409A of the Code and the regulations and other guidance thereunder. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(lll)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Section&#160;409A Change in Control&#8221; </font><font style="font-weight:normal;color:#000000;">means a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company&#8217;s assets, as provided in Section&#160;409A(a)(2)(A)(v) of the Code and Treasury Regulations Section&#160;1.409A-3(i)(5) (without regard to any alternative definition thereunder). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(mmm)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Securities Act&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Securities Act of 1933, as amended. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(nnn)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Share Reserve&#8221;</font><font style="font-weight:normal;color:#000000;"> means the number of shares available for issuance under the Plan as set forth in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;2(a)</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ooo)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Stock Appreciation Right&#8221; </font><font style="font-weight:normal;color:#000000;">or </font><font style="font-style:italic;color:#000000;">&#8220;SAR&#8221;</font><font style="font-weight:normal;color:#000000;"> means a right to receive the appreciation on the Common Stock that is granted pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4</font><font style="font-weight:normal;color:#000000;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ppp)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;SAR Agreement&#8221;</font><font style="font-weight:normal;color:#000000;"> means a written agreement between the Company and a holder of a SAR evidencing the terms and conditions of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general terms and conditions applicable to the SAR and which is provided to a Participant along with the Grant Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(qqq)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Subsidiary&#8221;</font><font style="font-weight:normal;color:#000000;"> means, with respect to the Company, (i)&#160;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly or indirectly, Owned by the Company, and (ii)&#160;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(rrr)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Ten Percent Stockholder&#8221;</font><font style="font-weight:normal;color:#000000;"> means a person who Owns (or is deemed to Own pursuant to Section&#160;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(sss)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Trading Policy</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;"> means the Company&#8217;s policy permitting certain individuals to sell Company shares only during certain &#8220;window&#8221; periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to time. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ttt)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Unvested Non-Exempt Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior to the date of any Corporate Transaction. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(uuu)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-style:italic;color:#000000;">&#8220;Vested Non-Exempt Award&#8221;</font><font style="font-weight:normal;color:#000000;"> means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to the date of a Corporate Transaction. </font></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* * * * </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>hsdt-ex103_9.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
hsdt-ex103_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.70 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.3</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Standard Stock Option Grant Package</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HELIUS MEDICAL TECHNOLOGIES, INC. <br />STOCK OPTION GRANT NOTICE<br />(2022 EQUITY INCENTIVE PLAN) </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Helius Medical Technologies, Inc<font style="font-variant: normal;">., a Delaware corporation (the </font><font style="font-weight:bold;font-style:italic;font-variant: normal;">&#8220;Company&#8221;</font><font style="font-variant: normal;">), pursuant to its 2022 Equity Incentive Plan (the </font><font style="font-weight:bold;font-style:italic;font-variant: normal;">&#8220;Plan&#8221;</font><font style="font-variant: normal;">), has granted to you (</font><font style="font-weight:bold;font-style:italic;font-variant: normal;">&#8220;Optionholder&#8221;</font><font style="font-variant: normal;">) an option to purchase the number of shares of the Common Stock set forth below (the </font><font style="font-weight:bold;font-style:italic;font-variant: normal;">&#8220;Option&#8221;</font><font style="font-variant: normal;">). Your Option is subject to all of the terms and conditions as set forth in this Stock Option Grant Notice (the </font><font style="font-weight:bold;font-style:italic;font-variant: normal;">&#8220;Grant Notice&#8221;</font><font style="font-variant: normal;">) and in the Plan, the Stock Option Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock Option Agreement, as applicable. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:8.85%;width:92.31%;">
<tr>
<td style="width:49.23%;"></td>
<td style="width:43.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Optionholder:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Grant:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares of the Common Stock</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subject to Option:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price (Per Share):</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Exercise Price:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Type of Grant:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Incentive Stock Option] OR [Nonstatutory Stock Option]</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise and Vesting Schedule:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the Optionholder&#8217;s Continuous Service through each applicable vesting date, the Option will vest as follows:<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><font style="color:#auto;"></font></p></td>
</tr>
</table></div>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:9pt;color:#auto;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9pt;color:#auto;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</font></p></td>
<td valign="top" style="width:92.31%;">
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:7.69%;font-size:9pt;color:#auto;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;color:#000000;"> </font><font style="font-weight:bold;font-size:10pt;color:#000000;">Note to Draft</font><font style="font-size:10pt;color:#000000;">: To insert applicable vesting schedule</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Optionholder Acknowledgements:<font style="font-weight:normal;"> By your signature below or by electronic acceptance or authentication in a form authorized by the Company, you understand and agree that: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Option is governed by the Grant Notice, and the provisions of the Plan, the Stock Option Agreement and the Notice of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and the Stock Option Agreement (together, the </font><font style="font-weight:bold;font-style:italic;color:#000000;">&#8220;Option Agreement&#8221;</font><font style="color:#000000;">) may not be modified, amended or revised except in a writing signed by you and a duly authorized officer of the Company. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">If the Option is designated an Incentive Stock Option, it (plus other outstanding Incentive Stock Options granted to you) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">You consent to receive this Grant Notice, the Stock Option Agreement, the Plan and any other Plan-related documents (including the Prospectus) by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">You have read and are familiar with the provisions of the Plan, the Grant Notice, the Stock Option Agreement, the Notice of Exercise and the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Option Agreement, the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition of the Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE COMPANY:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">Helius Medical Technologies, Inc.</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPTIONHOLDER:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-variant: small-caps;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">[Insert Name]</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENTS<font style="font-weight:normal;">: Stock Option Agreement, 2022 Equity Incentive Plan, Notice of Exercise </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT I <br /><br />STOCK OPTION AGREEMENT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HELIUS MEDICAL TECHNOLOGIES, INC. <br />2022 EQUITY INCENTIVE PLAN<br /><br />STOCK OPTION AGREEMENT</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As reflected by your Stock Option Grant Notice (the <font style="font-weight:bold;font-style:italic;">&#8220;Grant Notice&#8221;</font>), Helius Medical Technologies, Inc., a Delaware corporation (the <font style="font-weight:bold;font-style:italic;">&#8220;Company&#8221;</font>) has granted you an option under its 2022 Equity Incentive Plan (the <font style="font-weight:bold;font-style:italic;">&#8220;Plan&#8221;</font>) to purchase a number of shares of the Common Stock at the exercise price indicated in your Grant Notice (the <font style="font-weight:bold;font-style:italic;">&#8220;Option&#8221;</font>). Capitalized terms not explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option Agreement. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The general terms and conditions applicable to your Option are as follows: </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Governing Plan Document.</font><font style="font-weight:normal;color:#000000;"> Your Option is subject to all the provisions of the Plan, including but not limited to the provisions in:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 6</font><font style="font-weight:normal;color:#000000;"> regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 9(e)</font><font style="font-weight:normal;color:#000000;"> regarding the Company&#8217;s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 8</font><font style="font-weight:normal;color:#000000;"> regarding the tax consequences of your Option.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Your Option is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Vesting.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">The provisions of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section 2</font><font style="font-weight:normal;color:#000000;"> shall not apply to your Option if you have entered into a written agreement with the Company that contains terms related to a 280G Payment (as defined below).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">Your Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan. Vesting will cease upon the termination of your Continuous Service. Notwithstanding the foregoing, if a Change in Control occurs and your Continuous Service has not terminated as of immediately prior to such Change in Control, then the vesting and exercisability of your Option will be accelerated in full upon such Change in Control. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">If any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction (a </font><font style="font-style:italic;color:#000000;">&#8220;280G Payment&#8221;</font><font style="font-weight:normal;color:#000000;">) would (i)&#160;constitute a &#8220;parachute payment&#8221; within the meaning of Section&#160;280G of the Code, and (ii)&#160;but for this sentence, be subject to the excise tax imposed by Section&#160;4999 of the Code (the </font><font style="font-style:italic;color:#000000;">&#8220;Excise Tax&#8221;</font><font style="font-weight:normal;color:#000000;">), then any such 280G Payment (a </font><font style="font-style:italic;color:#000000;">&#8220;Payment&#8221;</font><font style="font-weight:normal;color:#000000;">) shall be equal to the Reduced Amount. The </font><font style="font-style:italic;color:#000000;">&#8220;Reduced Amount&#8221;</font><font style="font-weight:normal;color:#000000;"> shall be either (x)&#160;the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y)&#160;the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x)&#160;or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x)&#160;of the preceding sentence, the reduction shall occur in the manner (the </font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Reduction Method</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;">) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the </font><font style="font-style:italic;color:#000000;">&#8220;</font><font style="font-style:italic;color:#000000;">Pro Rata Reduction Method</font><font style="font-style:italic;color:#000000;">&#8221;</font><font style="font-weight:normal;color:#000000;">). </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section&#160;409A of the Code that would not otherwise be subject to taxes pursuant to Section&#160;409A of the Code, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section&#160;409A of the Code as follows: (A)&#160;as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (B)&#160;as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (C)&#160;as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section&#160;409A of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section&#160;409A of the Code. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless you and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15)&#160;calendar days after the date on which your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as requested by you or the Company. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x)&#160;of the first paragraph of this <font style="text-decoration:underline;">Section&#160;2(b)</font> and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x)&#160;of the first paragraph of this <font style="text-decoration:underline;">Section&#160;2(b)</font>) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y)&#160;in the first paragraph of this <font style="text-decoration:underline;">Section&#160;2(b)</font>, you</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Exercise</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">You may generally exercise the vested portion of your Option for whole shares of the Common Stock at any time during its term by delivery of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Sections 4(i)</font><font style="font-weight:normal;color:#000000;">, </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">4(j)</font><font style="font-weight:normal;color:#000000;"> and </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">7(b)(v)</font><font style="font-weight:normal;color:#000000;"> of the Plan, which may restrict or prohibit your ability to exercise your Option during certain periods. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">To the extent permitted by Applicable Law, you may pay your Option exercise price as follows: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">cash, check, bank draft or money order; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">subject to Company and/or Committee consent at the time of exercise, pursuant to a &#8220;cashless exercise&#8221; program as further described in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(c)(ii)</font><font style="font-weight:normal;color:#000000;"> of the Plan if at the time of exercise the Common Stock is publicly traded; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">subject to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of the Common Stock as further described in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(c)(iii)</font><font style="font-weight:normal;color:#000000;"> of the Plan; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">subject to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a &#8220;net exercise&#8221; arrangement as further described in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(c)(iv)</font><font style="font-weight:normal;color:#000000;"> of the Plan. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">By accepting your Option, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of the Common Stock or other securities of the Company held by you, for a period of one hundred eighty (180)&#160;days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule&#160;2241 or any successor or similar rules or regulation (the &#8220;</font><font style="font-style:italic;color:#000000;">Lock-Up Period</font><font style="font-weight:normal;color:#000000;">&#8221;); </font><font style="font-style:italic;font-weight:normal;color:#000000;">provided, however</font><font style="font-weight:normal;color:#000000;">, that nothing contained in this section will prevent the exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of the Common Stock until the end of such period. You also agree that any transferee of any shares of the Common Stock (or other securities) of the Company held by you will be bound by this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;3(c)</font><font style="font-weight:normal;color:#000000;">. The underwriters of the Company&#8217;s stock are intended third party beneficiaries of this </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;3(c)</font><font style="font-weight:normal;color:#000000;"> and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Term</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;"> You may not exercise your Option before the commencement of its term or after its term expires. The term of your Option commences on the Date of Grant and expires upon the earliest of the following: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">immediately upon the termination of your Continuous Service for Cause; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">three months after the termination of your Continuous Service for any reason other than Cause, Disability or death; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">12 months after the termination of your Continuous Service due to your Disability; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">18 months after your death if you die during your Continuous Service; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">immediately upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(f)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">the Expiration Date indicated in your Grant Notice; or </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-weight:normal;color:#000000;">the day before the 10<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> anniversary of the Date of Grant. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the foregoing, if you die during the period provided in <font style="text-decoration:underline;">Section&#160;3(b)</font> or <font style="text-decoration:underline;">3(c)</font> above, the term of your Option shall not expire until the earlier of (i) 18 months after your death, (ii)&#160;upon any termination of the Option in connection with a Corporate Transaction, (iii)&#160;the Expiration Date indicated in your Grant Notice, or (iv)&#160;the day before the tenth anniversary of the Date of Grant. Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in <font style="text-decoration:underline;">Section&#160;4(i)</font> of the Plan. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain the federal income tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option and ending on the day three months before the date of your Option&#8217;s exercise, you must be an employee of the Company or an Affiliate, except in the event of your death or Disability. If the Company provides for the extended exercisability of your Option under certain circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more than three months after the date your employment terminates.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Withholding Obligations.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">As further provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;8</font><font style="font-weight:normal;color:#000000;"> of the Plan: (a)&#160;you may not exercise your Option unless the applicable tax withholding obligations are satisfied, and (b)&#160;at the time you exercise your Option, in whole or in part, or at any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a &#8220;cashless exercise&#8221; pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the withholding procedures established by the Company. Accordingly, you may not be able to exercise your Option even though the Option is vested, and the Company shall have no obligation to issue shares of the Common Stock subject to your Option, unless and until such obligations are satisfied. In the event that the amount of the Company&#8217;s withholding obligation in connection with your Option was greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold the proper amount. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Incentive Stock Option Disposition Requirement.</font><font style="font-weight:normal;color:#000000;">  If your Option is an Incentive Stock Option, you must notify the Company in writing within 15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within two years after the date of your Option grant or within one year after such shares of the Common Stock are transferred upon exercise of your Option. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Transferability</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Except as otherwise provided in </font><font style="text-decoration:underline;font-weight:normal;color:#000000;">Section&#160;4(e)</font><font style="font-weight:normal;color:#000000;"> of the Plan, your Option is not transferable, except by will or by the applicable laws of descent and distribution, and is exercisable during your life only by you. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Corporate Transaction</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:normal;color:#000000;">Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company, including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf with respect to any escrow, indemnities and any contingent consideration. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">No Liability for Taxes</font><font style="font-weight:normal;color:#000000;">.  As a condition to accepting the Option, you hereby (a)&#160;agree to not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;color:#000000;">related to tax liabilities arising from the Option or other Company compensation and (b)&#160;acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that the Option is exempt from Section&#160;409A only if the exercise price is at least equal to the &#8220;fair market value&#8221; of the Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates </font><font style="font-weight:normal;color:#000000;">in the event that</font><font style="font-weight:normal;color:#000000;"> the Internal Revenue Service asserts that such exercise is less than the &#8220;fair market value&#8221; of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Severability</font><font style="font-weight:normal;color:#000000;">.  If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Other Documents</font><font style="color:#000000;">. </font><font style="font-weight:normal;color:#000000;">You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule&#160;428(b)(1) promulgated under the Securities Act, which includes the Prospectus. In addition, you acknowledge and agree to be subject to the Company&#8217;s Trading Policy, which such Trading Policy has been or will be made available to you. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-weight:normal;margin-left:36pt;color:#000000;"></font><font style="font-variant: small-caps;color:#000000;">Questions</font><font style="color:#000000;">.</font><font style="font-weight:normal;color:#000000;">  If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable federal income tax consequences please see the Prospectus. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* * * * </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT II <br /><br />2022 EQUITY INCENTIVE PLAN</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTACHMENT III <br /><br />NOTICE OF EXERCISE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">HELIUS MEDICAL TECHNOLOGIES, INC. <br /><br />(2022 EQUITY INCENTIVE PLAN) <br /><br />NOTICE OF EXERCISE </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Helius Medical Technologies, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">642 Newtown Yardley Rd., Suite 100</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Newtown, Pennsylvania 18940 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Chief Executive Officer</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Exercise:<font style="font-size:10pt;">&nbsp;&nbsp;_____________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This constitutes notice to Helius Medical Technologies, Inc., a Delaware corporation (the <font style="font-weight:bold;font-style:italic;">&#8220;Company&#8221;</font>) that I elect to purchase the below number of shares of the Common Stock of the Company (the <font style="font-weight:bold;font-style:italic;">&#8220;Shares&#8221;</font>) by exercising my Option for the price set forth below. Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Grant Notice, Option Agreement or 2022 Equity Incentive Plan (the <font style="font-weight:bold;font-style:italic;">&#8220;Plan&#8221;</font>) shall have the meanings set forth therein, as applicable. Use of certain payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Option Agreement and the Plan. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:83.16%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of option (check one):</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive <font style="font-family:Segoe UI Symbol;">&#9744;</font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td colspan="2" valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.72%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonstatutory <font style="font-family:Segoe UI Symbol;">&#9744;</font></p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Grant:</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares as to which Option is exercised:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certificates to be issued in name of:</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total exercise price:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, check, bank draft or money order delivered herewith:</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares delivered herewith:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulation T Program (cashless exercise)</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CCEEFF" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:17.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="4" valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:21.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Value of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares pursuant to net exercise:</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.1%;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;white-space:nowrap;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:12.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By this exercise, I agree (i)&#160;to provide such additional documents as the Company may require pursuant to the terms of the Plan, (ii)&#160;to satisfy the tax withholding obligations, if any, relating to the exercise of this Option as set forth in the Option Agreement, and (iii)&#160;if this exercise relates to an incentive stock option, to notify the Company in writing within 15 days after the date of any disposition of any of the Shares issued upon exercise of this Option that occurs within two years after the Date of Grant or within one year after such Shares are issued upon exercise of this Option. </p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with </p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect to any shares of </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Common Stock</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other securities of the Company for a period of one hundred eighty (180)&#160;days following the effective date of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the </font><font style="font-weight:bold;">&#8220;</font><font style="font-weight:bold;font-style:italic;">Lock-Up Period</font><font style="font-weight:bold;">&#8221;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:100%;"><font style="text-decoration:underline;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gruxbwvmsjji000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gruxbwvmsjji000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "> 54# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /#****^+/N@K5\-?\ (R6'_745E5J^&O\
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MHU8RCK&Z_,]^EF$*]&49:2L_GIT*_P 8/^/+2_\ KH_\A7D]>L?&#_CRTO\
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MWJYK/]H^!+RZU+3GMY-/O)<FUD!^1SW&.W7O0!<,4>E?%"%;- L=[;'SHH^
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2N=29966$81!R0!GO\U%(9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>hsdt-20220216.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-18T16:18:58.9089357+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : cec83a0f4df2417cb0146cca29b59f8d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:hsdt="http://www.heliusmedical.com/20220216" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.heliusmedical.com/20220216" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.heliusmedical.com/20220216/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hsdt-20220216_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hsdt-20220216_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>hsdt-20220216_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-18T16:18:58.9089357+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : cec83a0f4df2417cb0146cca29b59f8d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>hsdt-20220216_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-02-18T16:18:58.9089357+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : cec83a0f4df2417cb0146cca29b59f8d -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.heliusmedical.com/20220216/role/TemplateLink" xlink:href="hsdt-20220216.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hsdt-20220216.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139735384032760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 16,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HELIUS MEDICAL TECHNOLOGIES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4787690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">642 Newtown Yardley Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newtown<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">18940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">944-6100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HSDT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>hsdt-8k_20220216_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hsdt-20220216.xsd" xlink:type="simple"/>
    <context id="C_0001610853_20220216_20220216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610853</identifier>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0001610853_20220216_20220216" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0001610853_20220216_20220216" id="F_000004">0001610853</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0001610853_20220216_20220216" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0001610853_20220216_20220216" id="F_000002">2022-02-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0001610853_20220216_20220216" id="F_000003">HELIUS MEDICAL TECHNOLOGIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001610853_20220216_20220216" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0001610853_20220216_20220216" id="F_000006">001-38445</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001610853_20220216_20220216" id="F_000008">36-4787690</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001610853_20220216_20220216" id="F_000009">642 Newtown Yardley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001610853_20220216_20220216" id="F_000010">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001610853_20220216_20220216" id="F_000011">Newtown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001610853_20220216_20220216" id="F_000012">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001610853_20220216_20220216" id="F_000013">18940</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001610853_20220216_20220216" id="F_000014">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001610853_20220216_20220216" id="F_000015">944-6100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0001610853_20220216_20220216" id="F_000016">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0001610853_20220216_20220216" id="F_000017">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0001610853_20220216_20220216" id="F_000018">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0001610853_20220216_20220216" id="F_000019">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0001610853_20220216_20220216" id="F_000020">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001610853_20220216_20220216" id="F_000021">HSDT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001610853_20220216_20220216" id="F_000022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001610853_20220216_20220216" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MU\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK
M>MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ
M!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.
M\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( %N!4E0'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ 6X%25)6UA(ON    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ 6X%25)E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !;@5)4
MQ!J2FDT$  #B$   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ 6X%25)^@&_"Q @  X@P   T
M     ( !D P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !;@5)4EXJ[',
M   3 @  "P              @ %L#P  7W)E;',O+G)E;'-02P$"% ,4
M" !;@5)4'#AEZC\!   \ @  #P              @ %5$   >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 6X%25"0>FZ*M    ^ $  !H
M ( !P1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M6X%25&60>9(9 0  SP,  !,              ( !IA(  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&      D "0 ^ @  \!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="hsdt-8k_20220216.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="hsdt-8k_20220216.htm">hsdt-8k_20220216.htm</File>
    <File>hsdt-20220216.xsd</File>
    <File>hsdt-20220216_lab.xml</File>
    <File>hsdt-20220216_pre.xml</File>
    <File>hsdt-ex101_8.htm</File>
    <File>hsdt-ex103_9.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gruxbwvmsjji000001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "hsdt-8k_20220216.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "hsdt-8k_20220216.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hsdt-20220216_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hsdt-20220216_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hsdt-20220216.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 122,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hsdt",
   "nsuri": "http://www.heliusmedical.com/20220216",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hsdt-8k_20220216.htm",
      "contextRef": "C_0001610853_20220216_20220216",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "hsdt-8k_20220216.htm",
      "contextRef": "C_0001610853_20220216_20220216",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.heliusmedical.com/20220216/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001564590-22-005702-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-005702-xbrl.zip
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M_#T)B(:&AIZ._A(#PR7)*UQ7)/^/"_$CP$(-Y('ND8'X@',L(#(6$+$+  ,
MB +TCP+\9P&=(R.GH*2BIJ&E(PVH9P;.@<C(SI&345"0DY-Z'Y'Z 7(6"M8K
M-]4ISQL[4/'YLDD^3B^DYM>H^<1N,K0G(/7 +XJ&]L+%2QR<@E>%A*^)2,O(
MRLDK*&IJ:>M =?7T3>_>,S.WL+1R=')V<75S]_ /" P*#@F%1S^)B8V+3TC,
M>/8\,RO[Q<N<HN*2TK+RBM=OWM?6U3<T?FAJ_MS9]:6[I_=KW_#(Z-@X:F)R
M:F%Q:7GEU^K:^@9Z_^ 0<W2,/<']M@L$D('^J_R/=K&0[#I'3DY&3O7;+M"Y
MX-\#6,@IKMRD9%4WIG+P/<\G^9B:32.]L.83#;^4R1[[ [\AV@L"T@N"Z-^F
M_<.R_SW#HOZO+/NG8?]MUQ1 3P8B71X9"P !CC>$J\/LT;;53^EO+(85,;+Q
M,!.!>@)[KOZ[4A[W%G[]N^5F-N_,7?+*WTRYRU:I?(OTW2^ 2#VB\#4C"+:,
MMQH[O;QI1?/8 MH0*M14_0!'V#1IDKOHS^'$2Y\'\$0R4MCLH?#)66#,J'F<
M*5AQS/'2^N7BN=)LC1@.?:N^P95R351%42*.;/5<HG#!OZLRTG6IRKB*PTH5
MM*D8?!0;3]OSK183!)9?/=/3#D^!'U1)N-=NK3FL_T@38S9#QG8L.[TC M5%
M[RO-.^WW)2T0*&-336P-1A.)OP:']&(V1%I1#>,HYD_27[F>N?;3^[9PJQW_
M>FL^ >9PB2(MIZ[-9@3Z-U2J6&-M=K3K#(4'%D;0,6#";8B*U(?+$ %^P;BS
M0/92IL6>L4LH EL;>-D=;R_H>5A$0ZZ_S#+]^*XR/UK2P*]!\4 ZG?6"4H'"
MG3E(Q?$F9CMLB0H?ZH[ #!&!IT@A9$2]GD:MK_(6#T]NN("CS-R!:F&BVVJ"
M<ZQVABR'F>E3=\P\SP5T7N'"ZRP91YD$SZ]>/0=389Q';4SV(WC-^XUF4I1+
MJ_'I[5)KGYO7S5,,3;]^F?=PF#E.\S=)%*Y*Y2U*% ;^'RM9IW!1(K9V)^IO
MAF=:M7,2@?2,3D)SXG <VG$C&48$:.W2]J7;;R!ZLK*)@"WXA'8?CDE+!J-7
M2HD "DK0:,UK^V:(MOR:A6B!KI[$V(S(&,SP8+S%A-Q<C).1/O HI<1R[?M_
M616WE0JZ/#J_(.YGR(R%TYT\8.GK*HX,$>!B%?7ZL!L+WA=4)\U?0@B<0-7<
M;B2?1$^\J#![[OC>4_0E&IK\8._+EU9)R]9?3F*T'VSN+PTW>^QW)('W64<Z
M-I,0BD.7+A*!!<\I(O#CJO<I'O*YC8TK&37 ?OC^;.BP,(%.F\V$(V$1P=*S
M4$E=7=+@WI5Q$G:O82G*'V<N2@3H7%"$QU*(N04"N^LB$I\TCL <00XID0)E
M3]-*ME?.3VO?N,3*ZPEW<BEY,Q6,CQ:';"8BKIBYTY..$/A=17/0L\7!I5CG
M'<]R-Q?6HC@CJ:C035MQ/S!KQ[+A,T*+T$$!DQP1>#+7E7_(GDTXL=]#NOR0
M$&S>.\KU5<K.LG:;F3@6U+D=?F"O'N)(T+85(K3QD6S1EA6X'W+:-946=R?_
MB(SY #] >.!UVN*+'_#MV*M5UCS;M#\](%U#=>6B:MQKF- MPO<Z=SQ2+F*8
M\N=6C^D6+(:T)KBKXY VFW!JCRZT8/*IS2Q[WYB);EHRD\?PE56(&1>]:TCI
MYN:[Y["FQJYR)8;-6(WB?Z@\'-ILYE_R ]@K%Y G'&*0S8JW;\;^R^.8/8<D
M@>\ZVF--#A'II>AH@G)=!VZ-"/2:/T.]#;]/!-+$KQ.:(?OLRYB=!XC$[[=J
MSZ8@D&^DDUM5(?M)N(3HS:0Z"WIV@G*T">YD.F$M(#F)883B%FRB&"\='B%U
MMACQ5K2/((;H-;A#ZA+';X[]V;SK+S4HNNY\6KQN+XT:[C^&#L<*B+,9Z[I2
MH<T)VIN&N%,PCLP\P[P*?X^$;_@@H;V'$#FVG*E["Z=$FN*I<_F9K^&RR(#9
M2,<RASL1L#$]H1U RR6(M\J5A^ZG''Q-)]?$]A+42 !P22&4.Y=^6K6WZ2%_
ME-1H7[ [:BYSO2N?2<="[%FO>D\_RR<D_RC&H,T.9] R>2NC:?#]*6CBKK&E
M[?>_%NISM-:;^ 4BGF^)Y@T^1#-U-DIZRAE>Y)@1<Z)=+\I26+1T2!=(:9:\
MP4N0.0AXUT^VE2.7@LZM+@&/-[9>7^P?9+2[_FU_HJ8K:^4##EE("+"0"*O_
M&\BJW\PN7FX)V1%?MKR2'LS_NI>OR3[!?E_H*XE9STZ&.18QAQ=C(<OWAA&;
MP]?/R,T'Z_]HW[O)UUU<:>%^LR3[^-HYA:G2VJ]O=[&WE16(@+H;Q'ZOVG^Q
M Q]%NOPF$C9A?>X"%U4SH9;\ELPK%N?*1SF_M:,E4LIF9.I7\$;?"EA37D7"
M@RIS@O%1V[_YLL;7&KP(P:>:@S'?(6>43Z3&/%L-BS;DW&'N%=IB^ZX>$GX^
MDF%P,JNQA3DF(K <,M*QC20D>1QS7J)PFL7^I3-2G3-U8)3(\?R<<6TZSJP^
M)+O+\(3+"_'3<$6#;.RALFGAG"WT(:RB4VR8BT_"#Z$_@:3>@^)3X:YG 1 <
M#3*X,-(<4H%%J8\(W.R'O]=EI/TLE]X=9LZ.IOIR<#M8-N'!"F]"PT_=\FRO
MS2W0Y@X$ M%=SE)++U;*2RP6&'*P.?+&6MIQ$X&\1O#Q\OA.[B*#D)F2)[(P
MDP@TO9*[=2@S_[!\MB@K3"G&2%(O(1)<JI8Z]"'@P5M%9A]M)8K!4K=JS86S
M\?JPPCK<\T6+))#7=]5P1D9#WQ&.560].[_R3J(P,DEU3?2?XFAY[Y]LJQ)&
M7%"MZ.[8*R7QBM_@3[FQP'XB CQ6]F<!B&71KYL_NX@ ^ZN7KJ=U$8@7)*7[
M#J=JPM\@ 5^$";=- DGWO[I;*-8-BW<][3JS,,_$6Y#FS,HE<<#Z!/7FS_9X
MQ2_7/',_51%8I.-6#N+L%$&0^. Q3O(QCG9$H$#E^ SKO5>F1]K5YU$49'7$
MD AT>!.!+Z0?=*8V1"#_-H1PUD$$+MJLXOEPQV>@W8[=3D0,>"]I<^Z0JITT
MFH' YB:Y&Z_L6H'-Z%.R[A5WU%T^ ,58<,VG;CV"O:ILS%$M+==Z/SMA,]T]
M4"==DTF.\[];P7(81-H@;[\A;C&_USP1.V>E.)@@)-+3VZAZ2W-]E" DLY4.
MR5S +L\T/JQ0.#R!K68'I4_.)$EQU:@,",@&\-#O'>,%%!=[A(F 5F3HL[Q0
M[NP-Q%.9G0OC/RP_OK/62-?J"&3QH0@-[IP)TQD2NZXZY_?.QD#XTT17)EEJ
M-$IF$O$Y; %)PM@9#K%7&"6.3>O,BN ;R:-Y+C;OPA&Y<KEQ%)ZX9QTO4-^4
M->L\+7;'&/4C.MINC@C0[,9VK%WM.%XGG5GK7U^RS1IGK[8UOT]W:LR,%A7F
MQ^J$J)X4DBG-Q337&I;]=,]0O=WBG>S_.:]]!O&R"OS?W$9=W.NV//]%G+.&
M1H#A WSI4O7(HCD^81^!<B($!#+&):%^V%TB0<!<CP@@=3L.6>Q5__7/[2@%
M2"(1V*?^':.MDBB/O(8TPR))!YO$A-M!''+NYS!+K6TK$=2#\C%?((<L=DIH
M, $JFH9;!1.B[;Z4(WHE1@@?R@E1HCWM_"3OO^)+0LT2R56X\SJ!_Z3TWFX<
M:25E][DC%!'0K@]+H6<V3PC7(FVG>_6LBW!ONW[1G@6R[$MR-+Z03&H.\T_@
M?87U?,P/(K!VM6VVE?_/=BSU2</*RYVRX ??ONL)[-^!C:BR6UO\)3K]K ;Y
MI.6&CWY/I#IWMQ[D:;7<ERGR*<8F:1?9"^^;PH(W:/-\\XU',+N6\*#2X))9
M\9GG VS]W5#?-:CO+::BOEB3MR"J"KZF7.^/.;+ONXU9ZIN$KNJ&,*#>'*H\
M2N.&T>E@2[VO3M0GF<4T<RR<9&^85^"E#JOWO^-01HV66SO\>5?7>B=+;HXW
M_)BTTGYXCCQ1D#91":1]6YM763)Q.UQ]OCPI\/OSM^L95HR;A%WD\(<W)YR'
M0CHVM=#)'UVF2!ZW&U7V#(C>KPZD6]9V_EL,7?8[/HO[_U9R(?\+R3WWB[)I
M+^EC'(-@U@_$//O!V2-2>&_+,ROU$19HBJT*/WUMJ9K[^N?DARN%Z<_(#R)#
M2AXGN9=ZR*%K)R=L;?A>26G2R5.-/#:#+%Q&(=88*A#S4D0@)@A,%_@D=G])
M+_.=%R24B=N"Z46$)N0Q\F[9A,7) 8&E+9@0.15'((-@31"?Y:I)L+QL1 0^
MNI(B7!QKSC ?.^-&Z?>QK]V&-DP1#*(Q:4+81\4>67;7]*KK3EM"GDC0]=.)
M'"T)F)NC10E:)Y#-]PC%S<VG6)+SYPO/QTQ"<KG5T' <72=X7V0=@EF_2*+!
MZM0?[6OOH$)H>X+Z!3#F)PFW,BLR&W/L)%JP_+[<01*%3#4H'W'_G481?] (
M-E&W>T(QA4"Q_0X-0W:[$"=<U9#-5P@<@P!]W (1P*=Q!I_5$X&AAW9+=C3S
MIVMU<Q?645+,_*QL+F* ;9^Y0%YG$(+VN/D2+Y(5FT 2DI3!TP1\Y33LD[+]
MHPO%BY6G\>!P59<NSV7F D:5]PS4'$)1D&6_$<AF(6G)VV%M(= _V_0L!G>'
M/3%_7:UK?Z+'HG#(BXN>:NVQP3HCW-L?BJ@'4Z_V.3:H'VXA#+O;;%UC?F6P
M97):?)1X_-AY\%;JY&OA#X-_78V"A5I=6PPI,8V%FI2 ?3Q^/:NR7\M&N-7D
M%@M=1F%MR%ZQV.U6NN5$-'K>;V^TE/_<?J/_4*6R4UFS))?)IFFDW\MB@MW[
M'C\_^E-Y6/Q1!T-([%P7W*@E05^WW*DF?\$S",-FGNA&X!V5OJZT)2D2.AV\
M8[/*T7,@;?+.!L?8-,<<8C)MQN +,,\Z[H(B5\^0Z.K$Q+XJX7MI8F-#52(C
MI1)N2E)?O-]*!$R7-30G]_ =1/](,]X06?TG&=N@IL-5,F&FWH$\T'L.G=>.
M9+JL0[QVM=':2>\.Q&]A]: C':4A@3?.%YM)IM8TXP<CLAQH#YTYW$4A>;FT
M1. 29*G?@#11&CXF5 7>T\V$W1\F IO%1."*G:'MB_S%6L]_ W^?H(]C,"H1
M1]^MJ8>RA">M_9<R8'?]>:#V!M=GP/IH;ZPY#RGIR&,F G-#=L/R1BH5#S2&
MM-EB??+9$<MVM229J"&IO$PH=YAWFK323!BTL;%&VYUU7HG2T[<^#H.$D%CH
MNWC]9('I[(Q=]]81-TDJLGY+Q5.D,C9SX25W=Z,K2^!T4D%'9VI*FJ'5(4Q^
MZK)H2/ZN@$?Y!H6^VGUU(/H398GK0'KO7E]&UU8&/Z69:51) %\;DSZV7$QV
M4>7.X&"ZVCG=>).(HBILW$*&(?_/M?=BM[JR&I_B25+A=,0SUF478F!70SY0
M=N>N[,Q0]1Y"I.I2ZJ_-Q?HWQ72W%<T1"Y+R9.@O/O".A,#;+AB):B^+2],!
M>AQ3-?G&N[MZL(44OX/@]-*?N6W!5^=6$[<"KL<<2%?*UDJ6>/@O:_E9;X09
M%W CHO%:!/YAY9,"M]7X$[\;8/Y7@?9[VW<C!!&]^4)G08:KMMJYN6TQ)68-
MZ6)&6BW&%PO JVT/L"-Z+>.MBD=!^E4WTRTH/>EIT_/._TO"%VJ.%TUC00Q2
M(W;7D-9#XLXU/]Z*NP(&#,TZ\US)D:"RKE2Y/X)PV%1X6,'<)NY1B2QU,KK/
MLE%6OELT^F\WP?:#I_-O/F5 5<3=1?34UOC\\LOPU]2#L]Q2&' OJFRR^\?$
M-"EP#.6_!S$243&\TSA6-[DE\?R%BXVL8NI\FH^/A]'@*QQ7XJZT?4)C@U$/
M9;'W49WZ8V%/A<-!Y/B;33"C3!C'Q$3Y]'TAVKN11"#^K2[^>K6!DEJ.[==T
M>-0+\,O%"BBT"G^KHR/6((Q:^Y77#:>9ES>WPL#P1>=8"_T$XZ?OXXPZ.:@*
MD5I[@YWNX<O-XQ]9JCD>/E\FP0XV/96[2 0H89P]\66MM8E78S+5Q'FY*3A!
M?5A^ E1<BM ,/B-'U6["W\(ETGT1?%DLU_L*> P=[((7TL@VX:X)8D@OAWC-
M\QG+NC1KVO!G10:7H7R5Q?22[WKY?PS?3\M+;:P@ I[M;[--!)>:''E5VYJV
M4V^NV[9GHTVTXJ^6.PDX]+RDZ0[=8:IW@^73>^X$WRXQ.')7/)$PN(+C*<9L
M3GUH09[#)H[KF);7%=#O)$33PD$_9_$FP\71LD&H\_IA\M04H4'E%89O-J3F
M;+CZI;SXE9D<MD1F.F)E^LN<DPR:!.$[MSN^-^?2+>1N=]4,5'YHC+S_XOG*
M]/14"C/]GM"3A_65ERO;="C=&M]H:+)_EVK96S_A%!W;WEZH:TR=G95)O30J
MPI<,")?Z9AAKLT7^?I@X@/SY4N/X9^)P_3S>[-$=2\(V./\7F\F;VG=W3;[=
M <@$4*4AF@O%-D\Z4'??TK<4UY/'.FX0HKGCE(^Z&7W*K[5HK2/CRS641UR-
M][I8YBO#HZ3$GD0$3HSP)<KS612F.*;HL-^]#S)$6K&L)$)[QU]OB^@_FC#6
M=O%0Y1T)(,F-P==O_C:O=&0SF.27#[EP8QPY ?=4#$WKAL5R]H_L)=AYST>%
MJD2RFYQV3=G]538U-W/GJW< F=9G605R)Q\J+B/*-O;O$]@E]5'O![4-S<$Y
M9E.)#@[/,'Q_!2]U,$W:#L!4IM_^:$KY&)-*+:]205925&GE<2'[Z,'.<$ .
M67XN(Y3;/8NSM*S4\6C:/=AZY;$+!9R+IT,?:-+VEPPY[4R_\Z,>+6CM[IR0
MN+J9;*XCJ//DUEMZYV!*;NK-'. 1>VX)+(MSB_5V^3>G5+F)KD([W[Q#S-C6
MM.5# =V(B9K04ME7#Y=>'>ZJ7:PH>H?QON@V);@Z>;V:1Z$A[F/"7]$[%("7
ML0TF.Z5.7$./=6I]LBBAS+.KD[988%^D$2]&BO<&M_*/27K^.5+QC:BJ+<RP
M<;AX]%>3Q;:@VMIN][P.E-M_^Z[T+L>:5>G4U+2=B^OIF[7^E@DG/S>RB,1"
MQ[>6'G+960W#%W(&/M^A3:][A<.LN5^TJGFHOVG(FE\W#?W5U\)$UZ.P!D\$
M?A2]=H=7Y=4Z26PY'UP1J-9_ZJ>2(F<X[ADH7RU0_Y>?M:[C\_>94YU(*Z!#
MV]][:8X1JA _M\I0U]S]Q9]P=-.JL7D@-K^,03^T9Y+Q)M^YCZOE^J21O+R1
M4 TI"QPRL>X1Y[SUK&W,B^03M]())A]%(\H!]OR2S9R@1E"V89.EQMG*6C^&
M*OU>O3?;&DY@DP(SH1<_F/7&,O*8K!3P'+*$(^(#VLRZ8?U*Z0)&U]PC3#BH
M5*!VW2_"#4JKGS0/Y;9_[CEG*%Z;.PUW5-$&8$,VK0CF< 6QUYQVNI83PCP&
M&$B,F\>L\+"T0?SV;G70MR4?+8WE?^SC"SM4?UPLL$73WT$^BW=:[Q,Y6(.!
M#03_S\=M)JF_I]7?#@<D#BS:4[]W7\@REU\J.!9ZAW1'-\:NH%6Z7[IRK=/R
M*V=(.>5V",_##ZQSKD:78R/ZMQJ8M\P4@I1K\TU@J0'<^E5M:1ZIJO+A8@\R
M5Y"_'$(,/LK:\>CN5$?9;*AQ??VJ->A,=8)91CEHLX]=$J[D_UII%N@\(!?$
M9JQM_,(\%WMPBS")-DLOCYL841<V$P)ND"?OA?1R(+6JY6R)0$;:PN"Q($$G
MA^SI^/5 ;^:U;8J?WLQ#11!8T.JW;"7H4FK8<94W:PMTX3JU[KN7+V^1:T&2
MXWOZL8?5Q=VR>YT+W ]TE^Z%&DDG4XGY%>=_-+^V6!E;M^?Z9,>(TDV+%8"S
M\E,^YKX05VEK[Y% 3V!]=N=V:?N/I1C^QI_@[Z]#-&9I\ :+'8J7EK_L7A[E
M"A^&CS%0+<H65L(:@E@GITK\V\>=9M)[QFO?R@Q [Z"KZ\O7:Z8YO)%<5/E!
M;+&> 3B<$>5."JM[NRJJ;E/-L5;VL[V@8=^E&(4>/#4A\ 6*=1HOE-WG8BK8
MKV-YYP9]G,+1-A9E6HB%+]UYJ&DZ6IVQ:=)JF#OD4U'P: @7H5';*E>J686'
M/%(-<M9SSOYE5Y! 0W50P' FI3&\^&-[6_LY YV6'*5:L)/_@ FZ%.>NRI8C
MK-\C,&_U^8/\Y0\JB@Y^")#-3T4BD. IHXL703H*3E6/-OO,R"Z[SO&,!1LU
M>#.'+-T9EF&2<*L[-57IVYYZ?[/'T//Y/(X32%*+NDZ'[1,7N<92A:'3ED\Y
M!HE$9^BM,5X^8(\ GXB:0XX8P0,>^<GA2N5K4[>LOF?"&.J_I'3YK:B?Q,[?
M3'MM>C(NT;886H?@9+ :IYXI?Y>VG"T/BO2:P18P6;S-9[%6O_KX==]>]S"=
MGL\7$/^RRN;E3Q'B+6CI;)B_-[T&<TEHZ"K$U'J*E!(DP<O/X*38LH!34P')
MI$Z-M7-AX7T^^=/Y<W*>?9M#B*M56]T>YBU+B(;UH>U$DW$GGA0$^!RNH^H#
M>, D5)D2 :]@\,!FPE#$%?NU'"W. -FL82CCEM3.U_X+6X_6X[<"XT=,L(^+
MW;.I*]TI:CY8U'SR"N$OHQRR#1G9ZJKI$[_"JN.7S ^\7O_BA\O*#ERT%=)%
MB?U*'+F;*/C2(KIN!\C<[5F]%WYS426X:RI_MK:AOO:^!/O=K&R%;BG"^N&F
M&@?<JQ91$H+LZG@PY#K:.HW,[WN@W'JQVZ>\VG#%3%IT.@7:S8D9&$O.,E6)
MNZ'K9PZ"%FRB2MVQ<@0=Y 62]@TC%$2$$<N%(4F$3Z1$2MT*^(6_$NJ_$/-^
M].J#*9V2[FOQMTY,KEU!#/KF,8I8[#@U[LDEY+#.?ZUXT5]X^D9_.?^!/!Y6
MN)>535F[MZAT^?'SY[V@'I%@+I8=D;BH0]U )CH87*6S,<OKFS,J.I-6'?]1
M&C3NKBCQJIVKOOY4[/KYZ>JMZF#G4 6(J5W(-W0(G=6[6;O+*EK:+%X?9F;K
M=!H7;TL2P#0E#28VF33LTY0+ONGYX?0!,K NN,@:F&&E?E;P15^:V(?3+>LJ
M $YNO_'L;,@&VCGM%DAW>=ME0SIK?V.E,<LH*/4#3W1.[W"$X(9Y3FG*LTFK
M-[>5?2]<?@^Z+X6:K89!IE3)6YM'ZU8;GQFV9E\=5XN JG0K!9)TBMYXW9[M
MBK4T'?=VS4%16B0U@4]%_LTL+7-_B4?.V4SQG-U7OT^?=;@G?'Q(F48;SJP\
M5KJRI7\7JX?1&]KQ*K3G$ZYM$'YQCDKEA)2WY'2/CAAC$2IC.Z^.AM>S378N
M[*_>K!DDXXY#C0Q'RHIC!F2/5#P^HVXUU30;F&<%YK GYS\%O3K_G;K:R_Z$
M[QT"I4D$BG/JZW(5"2$8Q'E[/2_&XO(5OCB(\,3-5\<?>>J?7<>G6_PC"QT:
M4+MLI5H;ZNOK^O!ZM$#459&RE3A:2-LQI$K.^OUH@/?%CGC>$<IRF"]UHNY3
MYZ6/7(>0F4T,EP^,MF<QJ,2YH?Z4H6RXGR?"<^GQIBU38GU5V.=CI@JQAFS%
M\!U^76X+Z8?1ZZ,.C^!YST'U"VVF.J-5KMGZR9HOY0Q9TAQ%TW]&<+<)O[%C
M'?(2-SFXVY8CVS3ZTMGYB0.SGQK'[H&QKBMQ\C\ 4$L#!!0    ( %N!4E0^
M4UC&NP0  'X6   1    :'-D="TR,#(R,#(Q-BYX<V2]6%MOVS84?A^P_\#Y
MJ<6J:^+$-I(4W=(  =RN<+*A;P5-'=M$*4HEJ<3^]R,I2Z9MV;.4='X)Q7/[
M>&X\S-7[9<K0$PA),W[=B_RPAX"3+*%\?MTKI(<EH;3W_N;77ZY^\SQT>W?_
M&7T@BC[!+96$9;(0\.;ATUOT]8_)&#V0!:08W6:D2($KY*&%4ODH")Z?G_UD
M1KG,6*&T*>F3+ V0YU6*_Q2 #0'=8@7(_D8H#N/8"V,O&CQ&%Z-H,.H/_&$X
M&)[U+W\/PU$8.@K^*<^ G-\(]?W0C_S+>. P?L'D.YX#NK]U& F0P1D.9^?)
M+#Z/+LDTC,XO",'Q<-H?S@:)BS3+5X+.%PJ](6\M1'U>SH$Q6*$[RC$G%#/T
M4)WT';KGQ$<?&$,3(R;1!"2()TC\M=:E3$:R])R.!I>CA4S4=<]QW0(8+60*
M"2686=<9NV$<7?36(@G06F(Y%<R70/QY]A1H@F&.?IQ7K#JJ:I6#K/EG6$[]
M3,R#BF(%O##RSJ)*2*I<-!LP%"M0LPIUR$!-:K  2[)HMF HVQ8H.8"%DBU&
M0W1<:7D-CC@,^T%)=% WXFU"RHLT;E(:AQJK B[IE(%GV$#8K)9>;"JK]O\<
MX[S1_8;08)%C2F3SD2UI[]!T*WW<<Y\%N@J53E*H^$E6<"56S>K7Q"T#C/+O
M1_0;\A3+6O]RC__YS')'P^$PL-0:2B&$;C^'L*RI6V 2)7:R;0N1)@>&;*-C
MG&HDL5*"3@L%=YE(;V&&"Z:#7_ ?!69T1B'139"!Z6!;# Y983$']1FG('-,
MH&6QZH)O\H?V7A1\_30NNVA/MP:$;'.@:9X)A<H>,<Z(S:DC$3!?7A5FSVQY
M4:S3R=?*>H@WHCZ4(\$+8539T G&)I4ZPZCJW-CO'[+<W!A.LRGWC1[O R>
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M:/D.F??&W6,%9FE?S/;>U1/S9[:\?O@/4$L#!!0    ( %R!4E2.XTD<C1X
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M]@Y-$=;K><)UQ91]E![W;,E=UD]66@'0V#5V[+KL$IN%[%*$0ET+IV9Z'4>
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M/[O1^?36'N-KU>S8IFO,K,-66Q^POQ0CNC31T]<+T)6)=%&OH\_!*GW^5;_
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M^.GR]&WPTS^#RU].@Y\^GIR_#3Z^"]Z>G9^^N?QX?O$Z>*>F91.5=\'1=V&
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MCNE@W@B=98RTF6-N^'"9QZ_9@WM<%^Z-BRD;7;BOUX7;_LA<X4+I-#+G<!R
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M*K4,S1/=NW'N=*+ Y\"<53,VV7\[O#@,9@JSL%E(1;1P)F1%'&4Z>ZNA&PB
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M3ZQJ,Q0@BRC%R"#M58/#-(C#] M8SCF(%M/UY?C]G</'W$%N]GD-Z[UQ49)
M@>^2I=QFQMZZ%0$Q=TY &U^''F!^:'5B$"QX\3&=.:8S=YG.-,:J=_BSFI>^
M$0/'N4>S7176YM9[E'8FW3IKY@OL^& 9^^XD',?!+[U+-=FKRJ)%A4Z_L0*F
M449F =VSMDT2=;X0_.64$!""?A[-Z,W-Z.*12T,**5;S H\;!ZRT-6  (V@K
M8+JFNC,\LGC.<'[4)>NWEH0!@7&>1]A!G :%?(BU'#I6\:EFDW3+ZBYJ4?QO
MX7E@#:BPY[S#\BHP+&AH6#^W*,%V2A>9MEPY"20<&VGNEN.YCB^5W@G>3C@
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M+=#8LSET"; 9D[_"D6)37A@ O80 ^EIC]ELPR5YWGR,SQ7VM^ W9_S7S-BH
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M<GCLOJ;YIY738Q%79LA>V&UT#+(U=5X"KH;S *:W%-!J)!^[;51$7(RT&&'
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M6\ '(1^QAL.CH2>BK+_3;C5]K4_N."H9^'AVQD(=*:\$ =21\D=\A)6!_W,
M=I5!7@5]LXZ4;Q\:%<2,VF2O3?;:9*\CY546\%N,E(^3,$KP4N,X8+Z(4V=
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M,C$V7VQA8BYX;6Q02P$"% ,4    " !;@5)4^;0AK@L%  "&+0  %0
M        @ %O*0  :'-D="TR,#(R,#(Q-E]P<F4N>&UL4$L! A0#%     @
M7(%25([C21R-'@  E?@  !0              ( !K2X  &AS9'0M.&M?,C R
M,C R,38N:'1M4$L! A0#%     @ 7(%25#S*UBC/@   P; # !
M     ( !;$T  &AS9'0M97@Q,#%?."YH=&U02P$"% ,4    " !<@5)4L%JD
MY>TL   FOP$ $               @ %IS@  :'-D="UE>#$P,U\Y+FAT;5!+
4!08     !P ' ,<!  "$^P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
